Unplanned, fortunate discovery
POPULARITY
3 episodes with serendipitously
3 episodes with serendipitously
2 episodes with serendipitously
2 episodes with serendipitously
2 episodes with serendipitously
2 episodes with serendipitously
2 episodes with serendipitously
4 episodes with serendipitously
2 episodes with serendipitously
As we approach the final season of Andor, there is one character we've been expecting (and hoping) to see: the original Space-Papi, BAIL ORGANA played by the incomparable Jimmy Smits!Ever since his surprise appearance in Rogue One, and a larger and heartfelt role in Obi-Wan Kenobi, we've been wanting more and more of the Alderaanian senator. Serendipitously, a new trailer for Andor has dropped and our minds are racing! There's one scene in particular that has our speculation bordering on irresponsible!We discuss this new trailer and speculate why Bail Organa seems like a certainty in this series and what his potential role could be. We await the return of the king!• • •Triad of the Force is a channel which was featured on the Podcast Stage at Star Wars Celebration 2022 and 2023, featuring Nani and Gus, lifelong Puerto Rican friends who after years of discussing the media they love, came together and created their show. Triad of the Force focuses their discussions on Star Wars, but their love for media spans everything from sci-fi, fantasy, CBMs, and beyond. From films to TV, from books to comic books, Triad of the Force looks at all media critically, from a Latine/x perspective. Joins us!Follow Triad Of The Force at:BlueSky: https://bsky.app/profile/triadoftheforce.bsky.socialInstagram: https://www.instagram.com/triadoftheforce/YouTube: https://www.youtube.com/c/TriadoftheForce/If you like us, get some merch and help the channel:TeePublic: https://www.teepublic.com/user/triad-of-the-force• • •Acknowledgement: The Intro and Outro music is the Triad of the Force Theme, composed and performed by Grushkov with full permission for use by Grushkov (https://linktr.ee/Grushkov).• • •This channel is not affiliated in any way with Lucasfilm Ltd. LLC, The Walt Disney Company, or any of their affiliates or subsidiaries.
The Tapping Solution App: https://www.thetappingsolution.com/blog/tapping-solution-app/ Boundaries for Your Soul by Alison Cook: https://amzn.to/3Dtgs8d FRESH STARTS self-guided PDF (available for the first time!) now through January 10, 2025>>> https://elisabethklein.com/.../fresh-starts-self-guided-pdf/You know what comes after all of the chaos of December? The quiet of winter and the fresh start of the new year, which is the PERFECT time to do some self-reflection.I bet you'd love to take some deep breaths, press pause and reevaluate.How did your last year go? Are you the woman you want to be right now? What do you want for your future?How are you going to take care of yourself this year in new ways?I want to invite you to seek God, look back, look in, look up, and look ahead.Maybe your 2024 was really good. And that's so great! Then keep building on that!But maybe your 2024 was really horrible. That's okay too. Turn some pages, see what you can learn from last year, and recalibrate.In my self-guided PDF e-course, Fresh Starts, here's what you'll get:You will walk through four readings and four journaling exercises, and you will create a manifesto to propel you through the new year. You can order your PDF guide today: https://elisabethklein.com/.../fresh-starts-self-guided-pdf/All this jump-starting for only $15. (This is the lowest I've ever priced this course!)Let's wrap up 2024 and begin 2025 intentionally and with God.
Timestamps: 5:20 - Workaholics having fun 15:35 - Market validation 33:33 - Why Switzerland is the best headquarters 46:19 - Instilling company values 54:30 - Selling 100% of your shares About Fabio Ronga: Fabio Ronga is the co-founder and CEO of beqom, a cloud-based compensation management solution. He holds a master's degree in Business Information Systems from HEC Lausanne and previously worked at Hyperion (bought by Oracle) and Outlooksoft (bought by SAP) before starting beqom in 2008. Together with his co-founders (including Tanya Jansen and Stephan Pohl, who are still active in the company), Fabio built beqom to solve HR problems he himself had encountered earlier in his career. Serendipitously enough, someone Fabio used to know from Hyperion was on the board of a French company who had built the exact tech that Fabio and his co-founders needed, but was using it for different purposes. beqom was born out of a partnership with that company. Later on, when beqom was coming into its own, it merged with this French company. beqom started out with Swiss headquarters and maintains them to this day. Fabio thinks this helped them be global-minded about their product building from day one: since Switzerland is such a linguistically and culturally fragmented country, Swiss founders cannot rely on their domestic market to keep them in business, like US companies can. In 2022 beqom received a strategic investment of USD 300M from Sumeru Equity Partners. A few years prior, beqom had received another investment from Goldman Sachs, in exchange of which they promised a favorable exit scenario — this was their motivation for the 2022 Sumeru investment. The cover portrait was edited by www.smartportrait.io. Don't forget to give us a follow on Twitter, Instagram, Facebook and Linkedin, so you can always stay up to date with our latest initiatives. That way, there's no excuse for missing out on live shows, weekly giveaways or founders' dinners.
Julie Rose found her dream job in radio hosting. At the peak of the pandemic, the overwhelming mass of information coupled with the fear-mongering tendencies to drive engagement in the news left Julie feeling completely depleted. Was this the end of her dream career? Serendipitously, she was given the opportunity developed a radio show and podcast called "Top of Mind with Julie Rose" that recaps the news in a way that leaves the audience feeling empowered and optimistic rather than fearful and afraid. Challenging one's own worldview is essential to avoiding hyperemotional reactions rooted in our fragile ego. The point of gathering information is to learn, not to be right. Julie emphasizes that staying curious leads to increased empathy for others' lived experiences. That's what Christ-followers are called to do!In the social media age, actively resist the rage-bait. Tune into the news with a conscious, curious heart-posture. Check out Julie's podcast here. SUPPORT His Heartbeat through Crown of Beauty Internationalhttps://www.crownofbeautyinternational.com/donateCONNECT with His Heartbeat and Crown of Beauty InternationalWebsite// Facebook//InstagramEmail: crownofbeautyinternational@gmail.comConnect with Sue Corl's Instagram//Facebook// WebsitePurchase Sue's Transformational Bible Studies and Devotionals on Amazon!Sue Corl's best-selling books: Crown of Beauty Bible Study, Broken But UndefeatedCrown of Beauty International: EMPOWERING WOMEN AROUND THE WORLD WITH GOD'S TRUTH!
Pradeep is a brilliant geneticist and Director of Preventive Cardiology, holds the Paul & Phyllis Fireman Endowed Chair in Vascular Medicine at Mass General Hospital and on faculty at Harvard Medical School and the Broad Institute. His prolific research has been illuminating for the field of improving our approach to reduce the risk of heart disease. That's especially important because heart disease is the global (and US) #1 killer and is on the increase. We didn't get into lifestyle factors here since there was so much ground to cover on new tests. drugs, and strategies.A video snippet of our conversation on ApoB. Full videos of all Ground Truths podcasts can be seen on YouTube here. The audios are also available on Apple and Spotify.Transcript with links to key publications and audioEric Topol (00:06):Well, welcome to Ground Truths. I'm Eric Topol and with me is Pradeep Natarajan from Harvard. He's Director of Preventative Cardiology at the Mass General Brigham Health System and he has been lighting it up on the field of cardiovascular. We're going to get to lots of different parts of that story and so, Pradeep welcome.Pradeep Natarajan (00:31):Thanks Eric, really delighted and honored to be with you and have this discussion.Eric Topol (00:36):Well, for years I've been admiring your work and it's just accelerating and so there's so many things to get to. I thought maybe what we'd start off with is you recently wrote a New England Journal piece about two trials, two different drugs that could change the landscape of cardiovascular prevention in the future. I mean, that's one of the themes we're going to get to today is all these different markers and drugs that will change cardiology as we know it now. So maybe you could just give us a skinny on that New England Journal piece.Two New Lipid Targets With RNA DrugsPradeep Natarajan (01:16):Yeah, yeah, so these two agents, the trials were published at the same time. These phase two clinical trials for plozasiran, which is an siRNA against APOC3 and zodasiran, which is an siRNA against ANGPTL3. The reason why we have medicines against those targets are based on human genetics observations, that individuals with loss of function mutations and either of those genes have reduced lipids. For APOC3, it's reduced triglycerides for ANGPTL3 reduced LDL cholesterol and reduced triglycerides and also individuals that have those loss of function mutations also have lower risk for coronary artery disease. Now that's a very similar parallel to PCSK9. We have successful medicines that treat that target because people have found that carriers of loss of function mutations in PCSK9 lead to lower LDL cholesterol and lower coronary artery disease.(02:11):Now that suggests that therapeutic manipulation without significant side effects from the agents themselves for APOC3 and ANGPTL3 would be anticipated to also lower coronary artery disease risk potentially in complementary pathways to PCSK9. The interesting thing with those observations is that they all came from rare loss of function mutations that are enriched in populations of individuals. However, at least for PCSK9, has been demonstrated to have efficacy in large groups of individuals across different communities. So the theme of that piece was really just the need to study diverse populations because those insights are not always predictable about which communities are going to have those loss of function mutations and when you find them, they often have profound insights across much larger groups of individuals.Eric Topol (03:02):Well, there's a lot there that we can unpack a bit of it. One of them is the use of small interfering RNAs (siRNA) as drugs. We saw in the field of PCSK9, as you mentioned. First there were monoclonal antibodies directed against this target and then more recently, there's inclisiran which isn't an RNA play if you will, where you only have to take it twice a year and supposedly it's less expensive and I'm still having trouble in my practice getting patients covered on their insurance even though it's cheaper and much more convenient. But nonetheless, now we're seeing these RNA drugs and maybe you could comment about that part and then also the surprise that perhaps is unexplained is the glucose elevation.Pradeep Natarajan (03:53):Yeah, so for medicines and targets that have been discovered through human genetics, those I think are attractive for genetic-based therapies and longer interval dosing for the therapies, which is what siRNAs allow you to do because the individuals that have these perturbations, basically the naturally occurring loss of function mutations, they have these lifelong, so basically have had a one-time therapy and have lived, and so far, at least for these targets, have not had untoward side effects or untoward phenotypic consequences and only reduce lipids and reduce coronary artery disease. And so, instead of taking a pill daily, if we have conviction that that long amount of suppression may be beneficial, then longer interval dosing and not worrying about the pill burden is very attractive specifically for those specific therapeutics. And as you know, people continue to innovate on further prolonging as it relates to PCSK9.(04:57):Separately, some folks are also developing pills because many people do feel that there's still a market and comfort for daily pills. Now interestingly for the siRNA for zodasiran at the highest dose, actually for both of them at the highest doses, but particularly for zodasiran, there was an increase in insulin resistance parameters actually as it relates to hyperglycemia and less so as it relates to insulin resistance, that is not predicted based on the human genetics. Individuals with loss of function mutations do not have increased risks in hyperglycemia or type 2 diabetes, so that isolates it related to that specific platform or that specific technology. Now inclisiran, as you'd mentioned, Eric is out there. That's an siRNA against PCSK9 that's made by a different manufacturer. So far, the clinical trials have not shown hyperglycemia or type 2 diabetes as it relates inclisiran, so it may be related to the specific siRNAs that are used for those targets. That does merit further consideration. Now, the doses that the manufacturers do plan to use in the phase three clinical trials are at lower doses where there was not an increase in hyperglycemia, but that does merit further investigation to really understand why that's the case. Is that an expected generalized effect for siRNAs? Is it related to siRNAs for this specific target or is it just related to the platform used for these two agents which are made by the same manufacturer?Eric Topol (06:27):Right, and I think the fact that it's a mystery is intriguing at the least, and it may not come up at the doses that are used in the trials, but the fact that it did crop up at high doses is unexpected. Now that is part of a much bigger story is that up until now our armamentarium has been statins and ezetimibe to treat lipids, but it's rapidly expanding Lp(a), which for decades as a cardiologist we had nothing to offer. There may even be drugs to be able to lower people who are at high risk with high Lp(a). Maybe you could discuss that.What About Lp(a)?Pradeep Natarajan (07:13):Yeah, I mean, Eric, as you know, Lp(a) has been described as a cardiovascular disease risk factors for quite so many years and there are assays to detect lipoprotein(a) elevation and have been in widespread clinical practice increasing widespread clinical practice, but we don't yet have approved therapies. However, there is an abundance of literature preclinical data that suggests that it likely is a causal factor, meaning that if you lower lipoprotein(a) when elevated, you would reduce the risk related to lipoprotein(a). And a lot of this comes from similar human genetic studies. The major challenge of just relating a biomarker to an outcome is there are many different reasons why a biomarker might be elevated, and so if you detect a signal that correlates a biomarker, a concentration to a clinical outcome, it could be related to that biomarker, but it could be to the other reasons that the biomarker is elevated and sometimes it relates to the outcome itself.(08:10):Now human genetics is very attractive because if you find alleles that strongly relate to that exposure, you can test those alleles themselves with the clinical outcome. Now the allele assignment is established at birth. No other factor is going to change that assignment after conception, and so that provides a robust, strong causal test for that potential exposure in clinical outcome. Now, lipoprotein(a) is unique in that it is highly heritable and so there are lots of different alleles that relate to lipoprotein(a) and so in a well powered analysis can actually test the lipoprotein(a) SNPs with the clinical outcomes and similar to how there is a biomarker association with incident myocardial infarction and incident stroke, the SNPs related to lipoprotein(a) show the same. That is among the evidence that strongly supports that this might be causal. Now, fast forward to many years later, we have at least three phase three randomized clinical trials testing agents that have been shown to be very potent at lowering lipoprotein(a) that in the coming years we will know if that hypothesis is true. Importantly, we will have to understand what are the potential side effects of these medicines. There are antisense oligonucleotides and siRNAs that are primarily in investigation. Again, this is an example where there's a strong genetic observation, and so these genetic based longer interval dosing therapies may be attractive, but side effects will be a key thing as well too. Those things hard to anticipate really can anticipate based on the human genetics for off target effects, for example.(09:52):It's clearly a risk signal and hopefully in the near future we're going to have specific therapies.Eric Topol (09:57):Yeah, you did a great job of explaining Mendelian randomization and the fact the power of genetics, which we're going to get into deeper shortly, but the other point is that do you expect now that there's these multiple drugs that lower Lp(a) efficiently, would that be enough to get approval or will it have to be trials to demonstrate improved cardiovascular outcomes?Pradeep Natarajan (10:24):There is a great regulatory path at FDA for approval just for LDL cholesterol lowering and inclisiran is on the market and the phase three outcomes data has not yet been reported because there is a wide appreciation that LDL cholesterol lowering is a pretty good surrogate for cardiovascular disease risk lowering. The label will be restricted to LDL cholesterol lowering and then if demonstrated to have clinical outcomes, the label could be expanded. For other biomarkers including lipoprotein(a), even though we have strong conviction that it is likely a causal factor there hasn't met the bar yet to get approval just based on lipoprotein(a) lowering, and so we would need to see the outcomes effects and then we would also need to understand side effects. There is a body of literature of side effects for other therapies that have targeted using antisense oligonucleotides. We talked about potential side effects from some siRNA platforms and sometimes those effects could overtake potential benefits, so that really needs to be assessed and there is a literature and other examples.(11:31):The other thing I do want to note related to lipoprotein(a) is that the human genetics are modeled based on lifelong perturbations, really hard to understand what the effects are, how great of an effect there might be in different contexts, particularly when introduced in middle age. There's a lot of discussion about how high lipoprotein(a) should be to deliver these therapies because the conventional teaching is that one in five individuals has high lipoprotein(a), and that's basically greater than 75 nanomoles per liter. However, some studies some human genetic studies to say if you want to get an effect that is similar to the LDL cholesterol lowering medicines on the market, you need to start with actually higher lipoprotein(a) because you need larger amounts of lipoprotein(a) lowering. Those are studies and approaches that haven't been well validated. We don't know if that's a valid approach because that's modeling based on this sort of lifelong effect. So I'm very curious to see what the overall effect will be because to get approval, I think you need to demonstrate safety and efficacy, but most importantly, these manufacturers and we as clinicians are trying to find viable therapies in the market that it won't be hard for us to get approval because hopefully the clinical trial will have said this is the context where it works. It works really well and it works really well on top of the existing therapies, so there are multiple hurdles to actually getting it directly to our patients.How Low Do You Go with LDL Cholesterol?Eric Topol (13:02):Yeah, no question about that. I'm glad you've emphasized that. Just as you've emphasized the incredible lessons from the genetics of people that have helped guide this renaissance to better drugs to prevent cardiovascular disease. LDL, which is perhaps the most impressive surrogate in medicine, a lab test that you already touched on, one of the biggest questions is how low do you go? That is Eugene Braunwald, who we all know and love. They're in Boston. The last time I got together with him, he was getting his LDL down to close to zero with various tactics that might be extreme. But before we leave these markers, you're running preventive cardiology at man's greatest hospital. Could you tell us what is your recipe for how aggressive do you go with LDL?Pradeep Natarajan (14:04):Yeah, so when I talk to patients where we're newly getting lipid lowering therapies on, especially because many people don't have a readout of abnormal LDL cholesterol when we're prescribing these medicines, it's just giving them a sense of what we think an optimal LDL cholesterol might be. And a lot of this is based on just empirical observations. So one, the average LDL cholesterol in the modern human is about 100 to 110 mg/dL. However, if you look at contemporary hunter gatherers and non-human primates, their average LDL is about 40 to 50 and newborn babies have an LDL cholesterol of about 30. And the reason why people keep making LDL cholesterol lowering medicines because as you stack on therapies, cardiovascular disease events continue to reduce including down to these very low LDL cholesterol values. So the population mean for LDL cholesterol is high and everybody likely has hypercholesterolemia, and that's because over the last 10,000 years how we live our lives is so dramatically different and there has not been substantial evolution over that time to change many of these features related to metabolism.(15:16):And so, to achieve those really low LDL cholesterol values in today's society is almost impossible without pharmacotherapies. You could say, okay, maybe everybody should be on pharmacotherapies, and I think if you did that, you probably would reduce a lot of events. You'll also be treating a lot of individuals who likely would not get events. Cardiovascular disease is the leading killer, but there are many things that people suffer from and most of the times it still is not cardiovascular disease. So our practice is still rooted in better identifying the individuals who are at risk for cardiovascular disease. And so, far we target our therapies primarily in those who have already developed cardiovascular disease. Maybe we'll talk about better identifying those at risk, but for those individuals it makes lots of sense to get it as low as possible. And the field has continued to move to lower targets.(16:07):One, because we've all recognized, at least based on these empirical observations that lower is better. But now increasingly we have a lot of therapies to actually get there, and my hope is that with more and more options and the market forces that influence that the cost perspective will make sense as we continue to develop more. As an aside, related aside is if you look at the last cholesterol guidelines, this is 2018 in the US this is the first time PCSK9 inhibitors were introduced in the guidelines and all throughout that there was discussions of cost. There are a lot of concerns from the field that PCSK9 inhibitors would bankrupt the system because so many people were on statins. And you look at the prior one that was in 2013 and cost was mentioned once it's just the cost effectiveness of statins. So I think the field has that overall concern.(17:01):However, over time we've gotten comfortable with lower targets, there are more medicines and I think some of this competition hopefully will drive down some of the costs, but also the overall appreciation of the science related to LDL. So long-winded way of saying this is kind of the things that we discussed just to give reassurance that we can go to low LDL cholesterol values and that it's safe and then we think also very effective. Nobody knows what the lower limit is, whether zero is appropriate or not. We know that glucose can get too low. We know that blood pressure can be too low. We don't know yet that limit for LDL cholesterol. I mean increasingly with these trials we'll see it going down really low and then we'll better appreciate and understand, so we'll see 40 is probably the right range.Eric Topol (17:49):40, you said? Yeah, okay, I'll buy that. Of course, the other thing that we do know is that if you push to the highest dose statins to get there, you might in some people start to see the hyperglycemia issue, which is still not fully understood and whether that is, I mean it's not desirable, but whether or not it is an issue, I guess it's still out there dangling. Now the other thing that since we're on LDL, we covered Lp(a), PCSK9, the siRNA, is ApoB. Do you measure ApoB in all your patients? Should that be the norm?Measuring ApoBPradeep Natarajan (18:32):Yeah, so ApoB is another blood test. In the standard lipid panel, you get four things. What's measured is cholesterol and triglycerides, they're the lipids insoluble in blood to get to the different tissues that get packaged in lipoprotein molecules which will have the cholesterol, triglycerides and some other lipids and proteins. And so, they all have different names as you know, right? Low density lipoprotein, high density lipoprotein and some others. But also in the lipid panel you get the HDL cholesterol, the amount of cholesterol in an HDL particle, and then most labs will calculate LDL cholesterol and LDL cholesterol has a nice relationship with cardiovascular disease. You lower it with statins and others. Lower risk for cardiovascular disease, turns out a unifying feature of all of these atherogenic lipoproteins, all these lipoproteins that are measured and unmeasured that relate to cardiovascular disease, including lipoprotein(a), they all have an additional protein called ApoB. And ApoB, at least as it relates to LDL is a pretty good surrogate of the number of LDL particles.(19:37):Turns out that that is a bit better at the population level at predicting cardiovascular disease beyond LDL cholesterol itself. And where it can be particularly helpful is that there are some patients out there that have an unexpected ratio between ApoB and LDL. In general, the ratio between LDL cholesterol and ApoB is about 1.1 and most people will have that rough ratio. I verify that that is the expected, and then if that is the expected, then really there is no role to follow ApoB. However, primarily the patients that have features related to insulin resistance have obesity. They may often have adequate looking LDL cholesterols, but their ApoB is higher. They have more circulating LDL particles relative to the total amount of LDL cholesterol, so smaller particles themselves. However, the total number of particles may actually be too high for them.(20:34):And so, even if the LDL cholesterol is at target, if the ApoB is higher, then you need to reduce. So usually the times that I just kind of verify that I'm at appropriate target is I check the LDL cholesterol, if that looks good, verify with the ApoB because of this ratio, the ApoB target should be about 10% lower. So if we're aiming for about 40, that's like 36, so relatively similar, and if it's there, I'm good. If it's not and it's higher, then obviously increase the LDL cholesterol lowering medicines because lower the ApoB and then follow the ApoB with the lipids going forward. The European Society of Cardiology has more emphasis on measuring ApoB, that is not as strong in the US guidelines, but there are many folks in the field, preventive cardiologists and others that are advocating for the increasing use of ApoB because I think there are many folks that are not getting to the appropriate targets because we are not measuring ApoB.Why Aren't We Measuring and Treating Inflammation?Eric Topol (21:37):Yeah, I think you reviewed it so well. The problem here is it could be part of the standard lipid panel, it would make this easy, but what you've done is a prudent way of selecting out people who it becomes more important to measure and moderate subsequently. Now this gets us to the fact that we're lipid centric and we don't pay homage to inflammation. So I wrote a recent Substack on the big miss on inflammation, and here you get into things like the monoclonal antibody to interleukin-6, the trial that CANTOS that showed significant reduction in cardiovascular events and fatal cancers by the way. And then you get into these colchicine trials two pretty good size randomized trials, and here the entry was coronary disease with a high C-reactive protein. Now somehow or other we abandon measuring CRP or other inflammatory markers, and both of us have had patients who have low LDLs but have heart attacks or significant coronary disease. So why don't we embrace inflammation? Why don't we measure it? Why don't we have better markers? Why is this just sitting there where we could do so much better? Even agents that are basically cost pennies like colchicine at low doses, not having to use a proprietary version could be helpful. What are your thoughts about us upgrading our prevention with inflammation markers?Pradeep Natarajan (23:22):Yeah, I mean, Eric, there is an urgent need to address these other pathways. I say urgent need because heart disease has the dubious distinction of being the leading killer in the US and then over the last 20 years, the leading killer in the world as it takes over non-communicable diseases. And really since the early 1900s, there has been a focus on developing pharmacotherapies and approaches to address the traditional modifiable cardiovascular disease risk factors. That has done tremendous good, but still the curves are largely flattening out. But in the US and in many parts of the world, the deaths attributable to cardiovascular disease are starting to tick up, and that means there are many additional pathways, many of them that we have well recognized including inflammation. More recently, Lp(a) that are likely important for cardiovascular disease, for inflammation, as you have highlighted, has been validated in randomized controlled trials.(24:18):Really the key trial that has been more most specific is one on Canakinumab in the CANTOS trial IL-1β monoclonal antibody secondary prevention, so cardiovascular disease plus high C-reactive protein, about a 15% reduction in cardiovascular disease and also improvement in cancer related outcomes. Major issues, a couple of issues. One was increased risk for severe infections, and the other one is almost pragmatic or practical is that that medicine was on the market at a very high price point for rare autoinflammatory conditions. It still is. And so, to have for a broader indication like cardiovascular disease prevention would not make sense at that price point. And the manufacturer tried to go to the FDA and focus on the group that only had C-reactive protein lowering, but that's obviously like a backwards endpoint. How would you know that before you release the medicine? So that never made it to a broader indication.(25:14):However, that stuck a flag in the broader validation of that specific pathway in cardiovascular disease. That pathway has direct relevance to C-reactive protein. C-reactive protein is kind of a readout of that pathway that starts from the NLRP3 inflammasome, which then activates IL-1β and IL-6. C-reactive protein we think is just a non causal readout, but is a reliable test of many of these features and that's debatable. There may be other things like measuring IL-6, for example. So given that there is actually substantial ongoing drug development in that pathway, there are a handful of companies with NLRP3 inflammasome inhibitors, but small molecules that you can take as pills. There is a monoclonal antibody against IL-6 that's in development ziltivekimab that's directed at patients with chronic kidney disease who have lots of cardiovascular disease events despite addressing modifiable risk factors where inflammatory markers are through the roof.(26:16):But then you would also highlighted one anti-inflammatory that's out there that's pennies on the dollar, that's colchicine. Colchicine is believed to influence cardiovascular disease by inhibiting NLRP3, I say believed to. It does a lot of things. It is an old medicine, but empirically has been shown in at least two randomized controlled trials patients with coronary artery disease, actually they didn't measure C-reactive protein in the inclusion for these, but in those populations we did reduce major adverse cardiovascular disease events. The one thing that does give me pause with colchicine is that there is this odd signal for increased non-cardiovascular death. Nobody understands if that's real, if that's a fluke. The FDA just approved last year low dose colchicine, colchicine at 0.5 milligrams for secondary prevention given the overwhelming efficacy. Hasn't yet made it into prevention guidelines, but I think that's one part that does give me a little bit pause. I do really think about it particularly for patients who have had recurrent events. The people who market the medicine and do research do remind us that C-reactive protein was not required in the inclusion, but nobody has done that secondary assessment to see if measuring C-reactive protein would be helpful in identifying the beneficial patients. But I think there still could be more work done on better identifying who would benefit from colchicine because it's an available and cheap medicine. But I'm excited that there is a lot of development in this inflammation area.Eric Topol (27:48):Yeah, well, the development sounds great. It's probably some years away. Do you use colchicine in your practice?Pradeep Natarajan (27:56):I do. Again, for those folks who have had recurrent events, even though C-reactive protein isn't there, it does make me feel like I'm treating inflammation. If C-reactive protein is elevated and then I use it for those patients, if it's not elevated, it's a much harder sell from my standpoint, from the patient standpoint. At the lower dose for colchicine, people generally are okay as far as side effects. The manufacturer has it at 0.5 milligrams, which is technically not pennies on the dollar. That's not generic. The 0.6 milligrams is generic and they claim that there is less side effects at the 0.5 milligrams. So technically 0.6 milligrams is off label. So it is what it is.CHIP and Defining High Risk People for CV DiseaseEric Topol (28:40):It's a lot more practical, that's for sure. Now, before I leave that, I just want to mention when I reviewed the IL-1β trial, you mentioned the CANTOS trial and also the colchicine data. The numbers of absolute increases for infection with the antibody or the cancers with the colchicine are really small. So I mean the benefit was overriding, but I certainly agree with your concern that there's some things we don't understand there that need to be probed more. Now, one of the other themes, well before one other marker that before we get to polygenic risk scores, which is center stage here, defining high risk people. We've talked a lot about the conventional things and some of the newer ways, but you've been one of the leaders of study of clonal hematopoiesis of indeterminate potential known as CHIP. CHIP, not the chips set in your computer, but CHIP. And basically this is stem cell mutations that increase in people as we age and become exceptionally common with different mutations that account in these clones. So maybe you can tell us about CHIP and what I don't understand is that it has tremendous correlation association with cardiovascular outcomes adverse as well as other system outcomes, and we don't measure it and we could measure it. So please take us through what the hell is wrong there.Pradeep Natarajan (30:14):Yeah, I mean this is really exciting. I mean I'm a little bit biased, but this is observations that have been made only really over the last decade, but accelerating research. And this has been enabled by advances in genomic technologies. So about 10 years or plus ago, really getting into the early days of population-based next generation sequencing, primarily whole exome sequencing. And most of the DNA that we collect to do these population-based analyses come from the blood, red blood cells are anucleate, so they're coming from white blood cells. And so, at that time, primarily interrogating what is the germline genetic basis for coronary artery disease and early onset myocardial infarction. At the same time, colleagues at the Broad Institute were noticing that there are many additional features that you can get from the blood-based DNA that was being processed by the whole exome data. And there were actually three different groups that converged on that all in Boston that converged on the same observation that many well-established cancer causing mutations.(31:19):So mutations that are observed in cancers that have been described to drive the cancers themselves were being observed in these large population-based data sets that we were all generating to understand the relationship between loss of function mutations in cardiovascular disease. That's basically the intention of those data sets for being generated for other things. Strong correlation with age, but it was very common among individuals greater than 70; 10% of them would have these mutations and is very common because blood cancer is extremely, it's still pretty rare in the population. So to say 10% of people had cancer causing driver mutations but didn't have cancer, was much higher than anyone would've otherwise expected. In 2014, there were basically three main papers that described that, and they also observed that there is a greater risk of death. You'd say, okay, this is a precancerous lesion, so they're probably dying of cancer.(32:17):But as I said, the absolute incidence rate for blood cancer is really low and there's a relative increase for about tenfold, but pretty small as it relates to what could be related to death. And in one of the studies we did some exploratory analysis that suggested maybe it's actually the most common cause of death and that was cardiovascular disease. And so, a few years later we published a study that really in depth really looked at a bunch of different data sets that were ascertained to really understand the relationship between these mutations, these cancer causing mutations in cardiovascular disease, so observed it in enrichment and older individuals that had these mutations, CHIP mutations, younger individuals who had early onset MI as well too, and then also look prospectively and showed that it related to incident coronary artery disease. Now the major challenge for this kind of analysis as it relates to the germline genetic analysis is prevalence changes over time.(33:15):There are many things that could influence the presence of clonal hematopoiesis. Age is a key enriching factor and age is the best predictor for cardiovascular disease. So really important. So then we modeled it in mice. It was actually a parallel effort at Boston University (BU) that was doing the same thing really based on the 2014 studies. And so, at the same time we also observed when you modeled this in mice, you basically perturb introduce loss of function mutations in the bone marrow for these mice to recapitulate these driver mutations and those mice also have a greater burden of atherosclerosis. And Eric, you highlighted inflammation because basically the phenotype of these cells are hyper inflamed cells. Interestingly, C-reactive protein is only modestly elevated. So C-reactive protein is not fully capturing this, but many of the cytokines IL-1β, IL-6, they're all upregulated in mice and in humans when measured as well.(34:11):Now there've been a few key studies that have been really exciting about using anti-inflammatories in this pathway to address CHIP associated cardiovascular disease. So one that effort that I said in BU because they saw these cytokines increased, we already know that these cytokines have relationship with atherosclerosis. So they gave an NLRP3 inflammasome inhibitor to the mice and they showed that the mice with or without CHIP had a reduction in atherosclerosis, but there was a substantial delta among the mice that are modeled as having CHIP. Now, the investigators in CANTOS, the manufacturers, they actually went back and they survey where they had DNA in the CANTOS trial. They measured CHIP and particularly TET2 CHIP, which is the one that has the strongest signal for atherosclerosis. As I said, overall about 15% reduction in the primary outcome in CANTOS. Among the individuals who had TET2 CHIP, it was a 64% reduction in event.(35:08):I mean you don't see those in atherosclerosis related trials. Now this has the caveat of it being secondary post hoc exploratory, the two levels of evidence. And so, then we took a Mendelian randomization approach. Serendipitously, just so happens there is a coding mutation in the IL-6 receptor, a missense mutation that in 2012 was described that if you had this mutation, about 40% of people have it, you have a 5%, but statistically significant reduction in coronary artery disease. So we very simply said, if the pathway of this NLRP3 inflammasome, which includes IL-6, if you have decreased signaling in that pathway, might you have an even greater benefit from having that mutation if you had CHIP versus those who didn't have CHIP. So we looked in the UK Biobank, those who didn't have CHIP 5% reduction, who had that IL-6 receptor mutation, and then those who did have CHIP, if they had that mutation, it was about a 60% reduction in cardiovascular disease.(36:12):Again, three different lines of evidence that really show that this pathway has relevance in the general population, but the people who actually might benefit the most are those with CHIP. And I think as we get more and more data sets, we find that not all of the CHIP mutations are the same as it relates to cardiovascular disease risk. It does hone in on these key subsets like TET2 and JAK2, but this is pretty cool as a preventive cardiologist, new potential modifiable risk factor, but now it's almost like an oncologic paradigm that is being applied to coronary artery disease where we have specific driver mutations and then we're tailoring our therapies to those specific biological drivers for coronary artery disease. Hopefully, I did that justice. There's a lot there.Why Don't We Measure CHIP?Eric Topol (36:57):Well, actually, it's phenomenal how you've explained that, but I do want to review for our listeners or readers that prior to this point in our conversation, we were talking about germline mutations, the ones you're born with. With CHIP, we're talking about acquired somatic mutations, and these are our blood stem cells. And what is befuddling to me is that with all the data that you and others, you especially have been publishing and how easy it would be to measure this. I mean, we've seen that you can get it from sequencing no less other means. Why we don't measure this? I mean, why are we turning a blind eye to CHIP? I just don't get it. And we keep calling it of indeterminate potential, not indeterminate. It's definite potential.Pradeep Natarajan (37:51):Yeah, no, I think these are just overly cautious terms from the scientists. Lots of people have CHIP, a lot of people don't have clinical outcomes. And so, I think from the lens of a practicing hematologists that provide some reassurance on the spectrum for acquired mutation all the way over to leukemia, that is where it comes from. I don't love the acronym as well because every subfield in biomedicine has its own CHIP, so there's obviously lots of confusion there. CH or clinical hematopoiesis is often what I go, but I think continuing to be specific on these mutations. Now the question is why measure? Why aren't we measuring it? So there are some clinical assays out there. Now when patients get evaluated for cytopenias [low cell counts], there are next generation sequencing tests that look for these mutations in the process for evaluation. Now, technically by definition, CHIP means the presence of these driver mutations that have expanded because it's detectable by these assays, not a one-off cell because it can only be detected if it's in a number of cells.(38:55):So there has been some expansion, but there are no CBC abnormalities. Now, if there's a CBC abnormality and you see a CHIP mutation that's technically considered CCUS or clonal cytopenia of unknown significance, sometimes what is detected is myelodysplastic syndrome. In those scenarios still there is a cardiovascular disease signal, and so many of our patients who are seen in the cancer center who are being evaluated for these CBC abnormalities will be detected to have these mutations. They will have undergone some risk stratification to see what the malignancy potential is. Still pretty low for many of those individuals. And so, the major driver of health outcomes for this finding may be cardiovascular. So those patients then get referred to our program. Dana-Farber also has a similar program, and then my colleague Peter Libby at the Brigham often sees those patients as well. Now for prospective screening, so far, an insurance basically is who's going to pay for it.(39:51):So an insurance provider is not deemed that appropriate yet. You do need the prospective clinical trials because the medicines that we're talking about may have side effects as well too. And what is the yield? What is the diagnostic yield? Will there actually be a large effect estimate? But there has been more and more innovation, at least on the assay and the cost part of the assay because these initial studies, we've been using whole exome sequencing, which is continuing to come down, but is not a widely routine clinical test yet. And also because as you highlighted, these are acquired mutations. A single test is not necessarily one and done. This may be something that does require surveillance for particular high risk individuals. And we've described some risk factors for the prevalence of CHIP. So surveillance may be required, but because there are about 10 genes that are primarily implicated in CHIP, that can substantially decrease the cost of it. The cost for DNA extraction is going down, and so there are research tests that are kind of in the $10 to $20 range right now for CHIP. And if flipped over to the clinical side will also be reasonably low cost. And so, for the paradigm for clinical implementation, that cost part is necessary.Eric Topol (41:10):I don't know the $10 or $20 ones. Are there any I could order on patients that I'm worried about?Pradeep Natarajan (41:17):Not yet clinical. However, there is a company that makes the reagents for at least the cores that are developing this. They are commercializing that test so that many other cores, research cores can develop it. I think it's in short order that clinical labs will adopt it as well too.Eric Topol (41:36):That's great.Pradeep Natarajan (41:37):I will keep you apprised.What About Polygenic Risk Scores?Eric Topol (41:39):I think that's really good news because like I said, we're so darn lipid centric and we have to start to respect the body of data, the knowledge that you and others have built about CHIP. Now speaking of another one that drives me nuts is polygenic risk score (PRS) for about a decade, I've been saying we have coronary disease for most people is a polygenic trait. It's not just a familial hypercholesterolemia. And we progressively have gotten better and better of the hundreds of single variants that collectively without a parental history will be and independently predict who is at double, triple or whatever risk of getting heart disease, whereby you could then guide your statins at higher aggressive or pick a statin, use one or even go beyond that as we've been talking about. But we don't use that in practice, which is just incredible because it's can be done cheap.(42:45):You can get it through whether it's 23andMe or now many other entities. We have an app, MyGeneRank where we can process that Scripss does for free. And only recently, Mass General was the first to implement that in your patient population, and I'm sure you were a driver of that. What is the reluctance about using this as an orthogonal, if you will, separate way to assess a person's risk for heart disease? And we know validated very solidly about being aggressive about lipid lowering when you know this person's in the highest 5% polygenic risk score. Are we just deadheads in this field or what?Pradeep Natarajan (43:30):Yeah, I mean Eric, as you know, lots of inertia in medicine, but this one I think has a potential to make a large impact. Like CHIP mutations, I said news is about 10% in individuals greater than 70. The prospect here is to identify the risk much earlier in life because I think there is a very good argument that we're undertreating high risk individuals early on because we don't know how to identify them. As you highlighted, Dr. Braunwald about LDL cholesterol. The other part of that paradigm is LDL cholesterol lowering and the duration. And as we said, everybody would benefit from really low LDL cholesterol, but again, you might overtreat that if you just give that to everybody. But if you can better identify the folks very early in life, there is a low cost, low risk therapy, at least related to statins that you could have a profound benefit from the ones who have a greater conviction will have future risk for cardiovascular disease.(44:21):You highlighted the family history, and the family history has given the field of clues that genetics play a role. But as the genome-wide association studies have gotten larger, the polygenic risk scores have gotten better. We know that family history is imperfect. There are many reasons why a family member who is at risk may or may not have developed cardiovascular disease. A polygenic risk score will give a single number that will estimate the contribution of genetics to cardiovascular disease. And the thing that is really fascinating to me, which is I think some of a clinical implementation challenge is that the alleles for an individual are fixed. The genotyping is very cheap. That continues to be extremely cheap to do this test. But the weights and the interpretation of what the effects should be for each of the SNPs are continually being refined over time.(45:18):And so, given the exact same SNPs in the population, the ability to better predict cardiovascular diseases getting better. And so, you have things that get reported in the literature, but literally three years later that gets outdated and those hypotheses need to be reassessed. Today, I'll say we have a great relative to other things, but we have a great polygenic risk score was just reported last year that if you compare it to familial hypercholesterolemia, which has a diagnostic yield of about 1 in 300 individuals, but readily detectable by severe hypercholesterolemia that has about threefold risk for cardiovascular disease. By polygenic risk score, you can find 1 in 5 individuals with that same risk. Obviously you go higher than that, it'll be even higher risk related to that. And that is noble information very early in life. And most people develop risk factors later in life. It is happening earlier, but generally not in the 30s, 40s where there's an opportunity to make a substantial impact on the curve related to cardiovascular disease.(46:25):But there is a lot of momentum there. Lots of interest from NIH and others. The major challenge is though the US healthcare system is really not well set up to prevention, as you know, we practice healthcare after patient's developed disease and prevent the complications related to progression. The stakeholder incentives beyond the patient themselves are less well aligned. We've talked a lot here today about payers, but we don't have a single payer healthcare system. And patients at different times of their lives will have different insurers. They'll start early in life with their parents, their first employer, they'll move on to the next job and then ultimately Medicare. There's no entity beyond yourself that really cares about your longevity basically from the beginning and your overall wellness. That tension has been a major challenge in just driving the incentives and the push towards polygenic risk scores. But there are some innovative approaches like MassMutual Life Insurance actually did a pilot on polygenic risk scoring.(47:33):They're in the business of better understanding longevity. They get that this is important data. Major challenges, there are federal protections against non-discrimination in the workplace, health insurance, not necessarily life insurance. So I think that there are lots of things that have to be worked out. Everybody recognizes that this is important, but we really have to have all the incentives aligned for this to happen at a system-wide level in the US. So there's actually lots of investment in countries that have more nationalized healthcare systems, lots of development in clinical trials in the UK, for example. So it's possible that we in the US will not be the lead in that kind of evidence generation, but maybe we'll get there.The GLP-1 DrugsEric Topol (48:16):Yeah, it's frustrating though, Pradeep, because this has been incubating for some time and now we have multi ancestry, polygenic risk scores, particularly for heart disease and we're not using it, and it's not in my view, in the patient's best interest just because of these obstacles that you're mentioning, particularly here in the US. Well, the other thing I want to just get at with you today is the drugs that we were using for diabetes now blossoming for lots of other indications, particularly the glucagon-like peptide 1 (GLP-1) drugs. This has come onto the scene in recent years, not just obviously for obesity, but it's anti-inflammatory effects as we're learning, mediated not just through the brain but also T cells and having extraordinary impact in heart disease for people with obesity and also with those who have heart failure, about half of heart failure for preserved ejection fraction. So recently you and your colleagues recently published a paper with this signal of optic neuropathy. It was almost seven eightfold increase in a population. First, I wanted to get your sense about GLP-1. We're also going to get into the SGLT2 for a moment as well, but how do you use GLP-1? What's your prognosis for this drug class going forward?Pradeep Natarajan (49:55):As it relates to the paper, I can't claim credit as one of my former students who is now Mass Eye and Ear resident who participated, but we can talk about that. There's obviously some challenges for mining real world data, but this was related to anecdotes that they were observing at Mass Eye and Ear and then studied and observed an enrichment. In general though, I feel like every week I'm reading a new clinical trial about a new clinical outcome benefit as it relates to GLP-1 receptor agonists. This is kind of one thing that stands out that could be interrogated in these other clinical trials. So I would have that caveat before being cautious about ocular complications. But the data has been overwhelmingly beneficial, I think, because at minimum, obesity and inflammation are relayed to myriad of consequences, and I'm really excited that we have therapies that can address obesity that are safe.(50:52):There's a legacy of unsafe medicines for obesity, especially related to cardiovascular disease. So the fact that we have medicines that are safe and effective for lowering weight that also have real strong effects on clinical outcomes is tremendous. We in cardiology are increasingly using a range of diabetes medicines, including GLP-1 receptor agonists and SGLT2 inhibitors. I think that is also the secular changes of what influences cardiovascular disease over time. I talked about over the last 10 years or so with this increase in deaths attributable to cardiovascular disease. If you look at the influences of traditional clinical risk factors today, many of them have decreased in importance because when abnormal, we recognize them, in general we modify them when recognized. And so, many of the things that are unaddressed, especially the features related to insulin resistance, obesity, they start rising in importance. And so, there is a dramatic potential for these kinds of therapies in reducing the residual risks that we see related to cardiovascular disease. So I'm enthusiastic and excited. I think a lot more biology that needs to be understood of how much of this is being influenced specifically through this pathway versus a very effective weight loss medicine. But also interesting to see the insights on how the effect centrally on appetite suppression has profound influences on weight loss as well too. And hopefully that will lead to more innovations in weight management.The SGLT-2 DrugsEric Topol (52:25):And likewise, perhaps not getting near as much play, but when it came on the cardiovascular scene that an anti-diabetic drug SGLT2 was improving survival, that was big, and we still don't know why. I mean, there's some ideas that it might be a senolytic drug unknowingly, but this has become a big part of practice of cardiology in patients with diabetes or with preserved ejection fraction heart failure. Is that a fair summary for that drug?Pradeep Natarajan (53:00):Yeah, I totally agree. I mean, as there has been increased recognition for heart failure preserved ejection fraction, it has been almost disheartening over the last several years that we have not had very specific effective therapies to treat that condition. Now, it is a tremendous boon that we do have medicines interestingly focused on metabolism that are very helpful in that condition for heart failure with preserved ejection fraction. But there is still much more to be understood as far as that condition. I mean, the major challenge with heart failure, as you know, especially with heart failure preserved ejection fraction, it likely is a mix of a wide variety of different etiologies. So in parallel with developing effective therapies that get at some aspect is really understanding what are the individual drivers and then targeting those specific individual drivers. That requires a lot of unbiased discovery work and further profiling to be done. So lot more innovation, but relative to heart failure itself, it is not had widespread recognition as heart failure reduced ejection fraction. So much more to innovate on, for sure.Eric Topol (54:07):Right, right. Yeah, I am stunned by the recent progress in cardiovascular medicine. You have been center stage with a lot of it, and we've had a chance to review so much. And speaking of genetics, I wanted to just get a little insight because I recently came across the fact that your mother here at the City of Hope in Southern California is another famous researcher. And is that, I don't know what chromosome that is on regarding parental transmission of leading research. Maybe you can tell me about that.Pradeep Natarajan (54:41):Yeah, I mean, I guess it is a heritable trait when a parent has one profession that there is a higher likelihood that the offspring will have something similar. So both of my parents are PhDs, nonphysicians. There is a diabetes department at the City of Hope, so she's the chair of that department. So very active. We do overlap in some circles because she does investigate both vascular complications and renal complications. And then sometimes will ask my advice on some visualization. But she herself has just had a science translational medicine paper, for example, just a couple of months ago. So it's fun to talk about these things. To be honest, because my parents are researchers, I was not totally sure that I would be a researcher and kind of wanted to do something different in medicine. But many of my early observations and just how common cardiovascular disease is around me and in my community and wanting to do something useful is what got me specifically into cardiology.(55:45):But obviously there are numerous outstanding, important questions. And as I went through my career, really focused on more basic investigations of atherosclerosis and lipids. What got me excited sort of after my clinical training was the ability to ask many of these questions now in human populations with many new biological data sets, at least first centered on genetics. And the capabilities continue to expand, so now I teach first year Harvard medical students in their genetics curriculum. And when I talk to them just about my career arc, I do remind them they're all doing millions of things and they're exploring lots of things, but when they get to my shoes, the capabilities will be tremendously different. And so, I really advise them to take the different experiences, mainly in an exercise for asking questions, thoughtfully addressing questions, connecting it back to important clinical problems. And then once they start to understand that with a few different approaches, then they'll totally take off with what the opportunities are down the road.Eric Topol (56:51):No, it's great. I mean, how lucky somebody could be in the first year of med school with you as their teacher and model. Wow. Pradeep, we've really gone deep on this and it's been fun. I mean, if there's one person I'm going to talk to you about cardiovascular risk factors and the things that we've been into today, you would be the one. So thank you for taking the time and running through a lot of material here today, and all your work with great interest.Pradeep Natarajan (57:24):Thanks, Eric. I really appreciate it. It's tremendous honor. I'm a big fan, so I would be glad to talk about any of these things and more anytime.***************Thanks for listening, reading or watching!The Ground Truths newsletters and podcasts are all free, open-access, without ads.Please share this post/podcast with your friends and network if you found it informative!Voluntary paid subscriptions all go to support Scripps Research. Many thanks for that—they greatly helped fund our summer internship programs for 2023 and 2024.Thanks to my producer Jessica Nguyen and Sinjun Balabanoff for audio and video support at Scripps Research.Note: you can select preferences to receive emails about newsletters, podcasts, or all I don't want to bother you with an email for content that you're not interested in. Get full access to Ground Truths at erictopol.substack.com/subscribe
Heather's first baby was born via a traumatic cesarean after a grueling, two-day induction. She was told by the surgeon that her anatomy was such that she could never birth vaginally. That, plus the trauma of the induction experience, led her to choose an elective cesarean for her second baby, which at least offered her a degree of control. Serendipitously, one day at work, Heather found birth podcasts (like this one!) where other women shared their stories of free birthing - taking back their power from a system that says we need their interventions, their drugs, and surgeries in order to give birth. A lightbulb clicked on for her. She consciously conceived her third baby, and birthed her at home. In doing so, she birthed a new version of herself. If you love the show, I would greatly appreciate a review on Spotify or Apple Podcasts! Follow me on Instagram @healingbirth Do you have a birth story you'd like to share on the podcast, or would like to otherwise connect? I love to hear from you! Send me a note at contactus@healingbirth.net Check out the website for lots of other birth related offerings, and personalized support: www.healingbirth.net Intro / outro music: Dreams by Markvard
Hollie initially pursued a career in marine biology but found herself disenchanted with the industry. After exploring various job opportunities, she was diagnosed with ADHD. Serendipitously, she encountered an opportunity to train as an oil boiler engineer. Hollie successfully qualified and began working for a company in the field. In 2017, fueled by her passion and desire for autonomy, she took the bold step of establishing her own business. Becca faced academic challenges and was expelled from school for inadvertently causing a fire. Undeterred, she enrolled in college to learn about plumbing. Despite personal setbacks delaying her apprenticeship, Becca eventually started the program. Overcoming the gender biases on construction sites, she gained experience in social housing for several years. Transitioning to the private commercial sector, Becca found her niche, thoroughly enjoying her work with a company in the field. Guests this week: Hollie and Becca
Tony opens the show by talking about a change in Sports Center that he noticed, Dr J, and he also talks about about The Match with Michael. Michael Wilbon calls in to talk about going to see a high school basketball game between Gonzaga and Paul VI, Pat Forde calls in to talk about what needs to be done about students storming the court, and Tony closes out the show by opening up the Mailbag. Songs : Brian Kenneth Swain “Always” ; “Gravity” To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices
In today's episode of the "ON-AIR With MRGRIFFIS" podcast, hosted by Ryan Griffis, listeners are treated to an insightful conversation with Country Music Artist Justin Holmes. Ryan and Justin bond over their shared experiences in the military, expressing gratitude to their wives, whom they consider the true heroes enabling them to pursue their passions.Opening up about personal struggles, Justin emphasizes the importance of mental health. Ryan reassures listeners that life's challenges affect everyone, regardless of rank or title, advocating for taking a tactical pause but persevering through hardships.Justin recounts a pivotal moment when he almost gave up on music, only for his wife's encouragement to reignite his passion. Serendipitously, his song "Damn Addiction" gained traction on TikTok, with Ryan even creating a video to it before knowing Justin personally, demonstrating the power of unexpected connections.Reflecting on the transformative impact of his music, Justin accepts Ryan's invitation to perform at his compound, promising an intimate gathering of hometown friends around a campfire, showcasing his talent and heartfelt storytelling.Listeners are urged to check out Justin's latest release, "Drink You Down," available on all streaming platforms, encapsulating his authentic and emotive musical style.https://music.apple.com/us/album/drink-you-down/1727448438?i=1727448439https://www.instagram.com/justinholmesmusic?igsh=M2dxeTM4aGd0eTlshttps://www.instagram.com/countryrebel?igsh=MXdpbGY2aWJpbzcyYw==Support the show
Tiffany Hines is a coach for Youturn Health and works to help others find a stable life with new opportunities and hope for the future. She spent many years in and out of prisons and treatment centers until one day, she became open to change. Through love and support from her family, she dug into the 12-step program offered at the treatment center. From there, she moved into sober living and did everything they told her to do. She soon got her kids back, found somewhere to live, and got a job in a treatment center. Serendipitously, she came across our CEO in a meeting with her dad and the rest is history!Listen to Part One of her story here.
1-30-24 We're off to Arkansas tonight (where it's warmer) to visit with Tony Fry, owner and meadmaker at Arkansas Meadery in Alexander, Arkansas. Since 2001, Tony Fry has been deeply passionate about the art of fermenting, starting with beer and wine and eventually delving into the world of mead. As a founding member of CAF ("Central Arkansas Fermenters") in 2003, a prominent homebrew club based in Little Rock, Arkansas, he played a pivotal role in fostering a vibrant community of enthusiasts, making it one of the largest homebrew clubs in the United States. In 2014, Tony ventured into beekeeping, which further sparked his interest in mead-making. This journey led him to acquire a small farm in Saline County, Arkansas, in 2015. Serendipitously, that same year, the dry county lifted restrictions on alcohol sales, providing the perfect opportunity for Tony to explore his passion for mead-making and the possibility of opening a Meadery. Tony views this sequence of events as a divine sign, inspiring him to establish Arkansas's first Meadery, opening the meadery in September of 2021. Today, he is thrilled to share his creations with the world, inviting everyone to join the journey. This player will show the most recent show, and when we're live, will play the live feed. If you are calling in, please turn off the player sound, so we don't get feedback.[break] Sponsor: Honnibrook Craft Meadery. Rated the very best winery in Colorado! Visit our state-of-the-art meadery and tasting room south of downtown Castle Rock, Colorado, in a converted man cave. Mention the Got Mead Podcast this month for a free draft taster! Google H-O-N-N-I Brook for hours and directions. They love visitors! www.honnibrook.com If you want to ask your mead making questions, you can call us at 803-443-MEAD (6323) or send us a question via email, or via Twitter @realGotMead and we'll tackle it online! 9PM EDT/6PM PDT Join us on live chat during the show Upcoming Shows Show links and notes Let There Be Melomels by Rob Ratliff The Big Book of Mead Recipes by Rob Ratliff Let There Be Session Meads by Rob Ratliff Upcoming Events Valkyries Horn Mead Competition Home and Commercial Entries are open until Feb 2! Enter your Meads! Commercial https://commercial.valkyrieshorn.com/ and home https://comp.valkyrieshorn.com/ https://emmconference.comThe European Mead Makers Conference is coming up, and registration is open until Feb 18. The Mead Madness Cup is taking entry registrations until Jan 31. Registration for MMC https://meadmadnesscup.com/ Registration for EMMcon https://emmconference.com/ Feb 2 - The Green Lady, Chicago, IL - Hey Ciderfriends, Nice to Mead Ya - Mead Happy Hour Hang Feb 2 - Grimsby Hollow Meadery, Middleville, MI - Drink Mead, Learn Things - The English Longbow at War! Feb 3 - Four Brothers Mead, Festus, MO - John Jarrett Live Music Feb 4 - Lilly Belle Meads, Lancaster, NY - Brunch at the Meadery Feb 6 - Bee Well Mead and Cider, Bellaire, MI - Antrim Writers Series: Jerry Dennis Book Discussion Feb 8 - Breedens Orchard, Mount Juliet, TN - Mead 101, the Joy of Meadmaking Feb 8 - Adesanya Mead and Microbrewery, Grandville, MI - Open Mic Comedy Night Feb 9 - Clear Skies Meadery, Rockville, MD - Mead in Heaven Valentines Day pop up Feb 10 - Starrlight Meadery, Pittsboro, NC - Mead and Chocolate pairing Feb 10 - KingView Meadhouse, Harborcreek, PA - Galentine's Shopping Event Feb 14 - Bee Well Mead and Cider, Bellaire, MI - Valentines Day Book Fair for Grown Ups Feb 16 - Hickory Tree Farm Apiaries, Kent City, MI - Valentines Mead Make and Take Class Feb 17 - Harvest, Holland OH - Mead Day Celebration featuring meads from Schramm's, Four Fires and Meads of Midgard. Feb 17 - Perry Vine Mead and Cider, South Bend, IN - One Year Anniversary Celebration Feb 17 - Four Brothers Mead, Festus, MO - Oddsoul Duo Live Music Feb 18 - St.
Morgan Housel made his first investment when he was 18, putting $1,000 into a certificate of deposit at his local bank. When he started to make some interest on that investment, he was hooked. He devoured books on finance and economics, eventually becoming a financial columnist for The Motley Fool and The Wall Street Journal. In today's episode, Morgan shares why he thinks finance is more like psychology than physics, some of the common emotional pitfalls related to money, his secrets to staying rich, and much more. Morgan Housel is a partner at The Collaborative Fund. He's the author of the best-selling book The Psychology of Money. He is a two-time winner of the Best in Business Award from the Society of American Business Editors and Writers and winner of the New York Times Sidney Award. His latest book is Same As Ever: A Guide to What Never Changes. In this episode, Hala and Morgan will discuss: - Serendipitously finding a job he loves - The skiing accident that changed his life - What he learned from James Clear and Atomic Habits - How behavior can trump smarts - Why finance is more like psychology than physics - Independence and the purpose of wealth - Common emotional pitfalls related to money - Secrets to staying rich - What Bill Gates can teach you about optimism - Which unappreciated trait of Warren Buffet we should emulate - How stress can be a good thing - And other topics… Morgan Housel is a partner at The Collaborative Fund. He's the author of the best-selling book The Psychology of Money. He is a two-time winner of the Best in Business Award from the Society of American Business Editors and Writers and winner of the New York Times Sidney Award. In 2022, MarketWatch named him one of the 50 most influential people in markets. He serves on the board of directors at Markel. His latest book is Same As Ever: A Guide to What Never Changes. Resources Mentioned: Morgan's Website: https://www.morganhousel.com/ Morgan's LinkedIn: https://www.linkedin.com/in/morgan-housel-5b473821/ Morgan's Instagram: https://www.instagram.com/morganhousel/ Morgan's Twitter: https://twitter.com/morganhousel Morgan's Podcast: https://podcasts.apple.com/us/podcast/the-morgan-housel-podcast/id1675310669 Morgan's Book, Same as Ever (2023): https://www.amazon.com/Same-Ever-Guide-Never-Changes/dp/0593332709/ Morgan's Book, The Psychology of Money (2020):https://www.amazon.com/Psychology-Money-Timeless-lessons-happiness/dp/0857197681 LinkedIn Secrets Masterclass, Have Job Security For Life: Use code ‘podcast' for 30% off at yapmedia.io/course. Sponsored By: Shopify - Sign up for a one-dollar-per-month trial period at youngandprofiting.co/shopify Nom Nom - Go to youngandprofiting.co/trynomnom for 50% off on your two-week trial HelloFresh - Go to HelloFresh.com/profitingfree and use code profitingfree for FREE breakfast for life! Indeed - Get a $75 job credit at indeed.com/profiting More About Young and Profiting Download Transcripts - youngandprofiting.com Get Sponsorship Deals - youngandprofiting.com/sponsorships Leave a Review - ratethispodcast.com/yap Watch Videos - youtube.com/c/YoungandProfiting Follow Hala Taha LinkedIn - linkedin.com/in/htaha/ Instagram - instagram.com/yapwithhala/ TikTok - tiktok.com/@yapwithhala Twitter - twitter.com/yapwithhala Learn more about YAP Media Agency Services - yapmedia.io/
In episode 123, we welcome Kristin Tynski for a deep dive into the dynamic world of Generative AI.We chat about the wealth of new developments over the last year in Generative AI and some key takeaways from OpenAI's Dev Day presentation earlier this month. Kristin shares some thoughts on how organizations can effectively adopt Generative AI, offering actionable insights for businesses.We also discuss the importance of incorporating subject matter expertise into AI systems for enhanced accuracy and relevance and Kristin gives a few predictions for what the world of AI could look like in 2024.--------------(0:00) Intro(2:10) The Last Year in Generative AI(5:47) GPT 3.5 Expectations vs Reality(7:51) Biggest Takeaways from OpenAI Dev Day(11:17) How Your Organization Can Adopt Generative AI?(16:43) Incorporating Subject Matter Expertise(21:34) How Trustworthy are Generative AI Results?(24:50) AI Predictions for 2024(33:25) Rapid Fire Rankings-------------Top 3 of anything:• My Daughter• My Wife• Running a Family BusinessRank your best SEO marketing win:Serendipitously, in the months before that, I had been working on a content idea for a site called Lawsuit.org, owned by Fractl. The goal was to come up with something interesting and newsworthy. I realized through some Fractl work that my local county has a database of all arrest and traffic stop records.We undertook a large scraping project to gather all the data we could from Palm Beach County, looking at police activities, anomalies, and if certain officers had disproportionately high arrest rates of African American people. While we found some anomalies, nothing was super groundbreaking. However, it proved that you could scrape a county's police data and identify potential issues.I published this on Hacker News, Reddit, and other platforms. The content did really well, especially on Reddit, likely due to its coincidence with the George Floyd situation. People were looking for tangible ways to contribute.I suggested on Reddit the idea of doing this for every county, not just Palm Beach County. The Reddit post went viral, leading to a Slack group where about 2,500 people joined in a few days. It self-organized from there, with little input from me after the first few weeks, turning into a community. A law firm helped turn it into a nonprofit, which received $250,000 in funding.Rank your top 3 SEO tools:• SEMRush• Ahrefs• SERP APIBONUS: AppifyRank your best SEO or trick or tactic:Creating content that is truly adding new and newsworthy information, which requires doing some sort of data analysis.You need to create something really that hasn't existed before, and that is adding value in an entirely new way.Rank what you love most about the SEO industry:I love how dynamic it is. I love how quickly it changes.Rank your top 1-3 marketers:• Mike King• Britney Muller• Rand FishkinRank your best SEO learning resource:I think for the more advanced stuff, you're going to find the most interesting, cutting-edge stuff inside of closed groups.Rank your top cause or charity:Police Data Accessibility ProjectMedical Aid for Palestinians
When he first came to the U.S. from India at age 21, Sachin was eager to build a lifestyle fueled by alcohol and partying. Actually, it was a continuation of the life he lived in India where the shame, guilt, and low self-esteem created by his dysfunctional family only made Sachin want to drink more. After years in the U.S., Sachin's daily drinking, coupled with his desire to dominate business and personal relationships, had ironically become the blueprint for his inevitable demise. For the next 15 years, Sachin's functional alcoholism aided his relative success in his business and personal lives. Surrounding himself with a group of people who drank and partied like he, Sachin still felt something had been lost in the fog of his disease. A brief break in the fog gave him a glimpse of what had been missing--spirituality. Serendipitously, that realization coincided with his entrée into Alcoholics Anonymous, in 2020. Sachin's subsequent quest for a spiritual awakening became the driving force in his Program since the beginning. Today, he gratefully acknowledges that he found what he'd been looking for by active work and sincere participation in all aspects of AA. By living the Program and practicing the principles in his affairs, Sachin enjoys a rich life that he shares with his family and his fellows in AA, freely admitting that he could not have achieved what he has with Alcoholics Anonymous. So please enjoy the next hour and fifteen minutes of AA Recovery Interviews with my friend and AA brother, Sachin B. If you've enjoyed my AA Recovery Interviews series and my Big Book podcast, have a listen to Lost Stories of the Big Book, 30 Original Stories Missing from the 3rd and 4th Editions of Alcoholics Anonymous. It's an engaging audiobook I narrated to bring these stories to life for AA members who've never seen them. These timeless testimonials were originally cut to make room for newer stories in the 3rd and 4th Editions. But their vitally important messages of hope are as meaningful today as when they were first published. Many listeners will hear these stories for the first time. Lost Stories of the Big Book is available on Audible, Amazon, and iTunes. It's also available as a Kindle book and in Paperbackfrom Amazon if you'd like to read along with the audio. I also invite you to check out my latest audio book, “Alcoholics Anonymous: The Story of How More Than One Hundred Men Have Recovered From Alcoholism”. This is the word-for-word, cover-to-cover reading of the First Edition of the Big Book, published in 1939. It's a comfortable, meaningful, and engaging way to listen to the Big Book anytime, anyplace. Have a free listen at Audible, i-Tunes, or Amazon. [Disclaimer: AA Recovery Interviews podcast strictly adheres to AA's 12 Traditions and all General Service Office guidelines for safe-guarding anonymity on-line. I pay all podcast production costs and no one receives financial gain from the show. AA Recovery Interviews and my guests do not speak for or represent AA at-large. This podcast is simply my way of giving back to AA that which has been so freely given to me. -Howard L.]
In this episode, Adam and Budi conclude their 2023 Book Club series with a deep dive into 'The Art of Gathering' by Priya Parker. We look at the transformative impact this text had on Adam's professional journey. Serendipitously, we were able to record this episode on the day of Budi's PhD Seminar which allowed us to reflect on the power of intentional gatherings and the subsequent impact of shared experiences.Priya Parker's bold approach to gatherings redefines the ways people connect, learn, and develop relationships. The acclaimed author of The Art of Gathering: How We Meet and Why it Matters, executive producer and host of the New York Times podcast, Together Apart, and the founder of boutique advisory firm Thrive Labs, she helps activists, elected officials, corporate executives, educators, and philanthropists create transformative, unforgettable gatherings that allow them to step back from their daily routine, rediscover their motivations, and develop strategies for innovation.In The Art of Gathering, Parker combines fascinating case studies culled from an international cast of characters with practices to follow—and rules to break— to connect more meaningfully with friends, colleagues, and strangers. She includes examples from her attempts to create connections, illustrating which tactics worked and which ones failed. Included among her success stories are “#IamHere Days,” self-organized adventures in which a group of people unplugs and explores a neighborhood, and “15 Toasts,” dinner parties where each guest has to toast to a common theme (the twist: the last one has to sing their toast). Parker's interactive talks are both a demonstration of the techniques described in her books and a guide on how to implement her strategies.Parker has helped numerous clients develop better in-person and virtual gatherings, including the Museum of Modern Art, LVMH, the World Economic Forum, meetup.com, and Civitas Public Affairs. Trained in conflict resolution, she has worked on peace processes in the Arab world, Southern Africa, and India, and is a founding member of the Sustained Dialogue Campus Network, where she worked on race relations on American college campuses. She has been appointed as a member of the World Economic Forum Global Agenda Council on Values and the New Models of Leadership Council, and is also a senior expert at Mobius Executive Leadership.Parker's The Art of Gathering: How We Meet and Why It Matters has been named a Best Business Book of the year by Amazon, Esquire Magazine, NPR, the Financial Times, 1-800-CEO-READS and Bloomberg. She has spoken on the TED Main Stage, and her TEDx talk on purpose has been viewed over one million times.Her work has been featured in The New York Times, the Wall Street Journal, Forbes.com, Oprah.com, Real Simple Magazine, Glamour, The Today Show, and Support the showPlease help us send BRIGHT LIGHT BURNING to COP28 in Dubai. Support us on our GoFundMe FundraiserIf you enjoyed this week´s podcast, please leave a review on Apple Podcasts. To submit a question: Voice- http://www.speakpipe.com/theatreofothers Email- podcast@theatreofothers.com Support the Theatre of Others - Check out our Merch!Show Credits Co-Hosts: Adam Marple & Budi MillerProducer: Jack BurmeisterMusic: https://www.purple-planet.comAdditional compositions by @jack_burmeister
Adam Sawyer built a writing career from the depths of heroin addiction writing about what helped him through that, which was communing with nature. Serendipitously, it was in nature where he met the love of his life, Kara, with whom he bought a home off the grid in Washington to base their lives together. While away on a business trip less than two years ago, a fire took away virtually every single thing in his life. His life partner, his home, and his cherished cat, not to mention all his possessions. Adam's grieving journey has been quite difficult, but once again he found himself seeking open spaces to help him through his horrific thoughts and emotions. Just recently Adam declared himself in an emotional place to start mingling with people, and so he has begun giving talks about the grieving process at libraries and other places. We invited Adam to share some of his realizations and processes with us on the podcast in a fascinating hour-plus talk about what he's been through. As with most all RATF episodes, we hear about some of Adam's favorite spots to eat, too. Adam's writings can be found at https://substack.com/@adamsawyer Right at the Fork is supported by: Zupan's Markets: www.Zupans.com RingSide Steakhouse: www.RingSideSteakhouse.com Portland Food Adventures: www.PortlandFoodAdventures.com
This week, as the last episode in our mini-series featuring the founders of Parfait, Co-Founder and CMO, Simone Kendle dives into the importance of understanding the customer experience and the product development process. She also discusses the decision to rebrand the company from “Hair Intelligence” to “Parfait” saying “And we really decided that at that point, we wanted to redefine a word for ourselves. And that's where Parfait comes in, right? The word literally has AI in it.” Simone also emphasizes her appreciation for having co-founders, Isoken Igbinedion and Ifueko Igbinedion, who have complementary skill sets and how they all fit together to shape the direction of the company. As an operations manager by trade turned stylist and founder of two hair businesses prior to launching Parfait, Simone credits community support and the commitment to her entrepreneurial passion as the guiding principles of the brand's success. Follow @simonekendle, @my.parfait or visit https://myparfait.com/! In the spring of 2021, Simone was approached by Iso to join Parfait. At the time, Simone had just finished her MBA program at Wharton Business school and was set to return to her previous employer, Capital One, with no intention of looking elsewhere. As the school year ended, Kendle realized she needed to take a leap of faith toward her entrepreneurial dreams and set aside the security of working in corporate America. This meant fully committing to the entrepreneurial community, but in what capacity was still unclear. Serendipitously, just weeks later, Iso and Simone met for happy hour, where Iso convinced Simone to join the growing team. Simone graduated from the University of North Texas with a degree in operations management. She interned at Capital One throughout college and built a career across operations, process management, and customer insights strategy roles. During her college years, she started two hair businesses, one while in school and her second business once she graduated, which she ran for five years alongside building her career at Capital One. To finally bring her two career paths together, she decided to return to school and get her MBA at Wharton Business School. With a deep knowledge of the wig industry's product and customer experiences, coupled with formal customer insights strategy experience gained from Capital One and elite business skill building from Wharton, joining Parfait was a no-brainer for Simone. In her spare time, Simone watches after her daughter Kaia and takes her to dance classes where she is on a local majorette competition team—Simone is slowly becoming a dance mom. When the workday is over, you can catch her snuggled up with Kaia watching Disney's latest release or jamming out to some old-school R&B. Influencer & Brand Shout-Out: @swellabeauty “I can accomplish anything I put my mind to. If it's aligned to what God has called me to do and he told me, then I'm doing it.” Simone's Word of 2023: Parfait Tune in to learn more from Kendra and Simone!See omnystudio.com/listener for privacy information.
This week, as the last episode in our mini-series featuring the founders of Parfait, Co-Founder and CMO, Simone Kendle dives into the importance of understanding the customer experience and the product development process. She also discusses the decision to rebrand the company from “Hair Intelligence” to “Parfait” saying “And we really decided that at that point, we wanted to redefine a word for ourselves. And that's where Parfait comes in, right? The word literally has AI in it.” Simone also emphasizes her appreciation for having co-founders, Isoken Igbinedion and Ifueko Igbinedion, who have complementary skill sets and how they all fit together to shape the direction of the company. As an operations manager by trade turned stylist and founder of two hair businesses prior to launching Parfait, Simone credits community support and the commitment to her entrepreneurial passion as the guiding principles of the brand's success. Follow @simonekendle, @my.parfait or visit https://myparfait.com/! In the spring of 2021, Simone was approached by Iso to join Parfait. At the time, Simone had just finished her MBA program at Wharton Business school and was set to return to her previous employer, Capital One, with no intention of looking elsewhere. As the school year ended, Kendle realized she needed to take a leap of faith toward her entrepreneurial dreams and set aside the security of working in corporate America. This meant fully committing to the entrepreneurial community, but in what capacity was still unclear. Serendipitously, just weeks later, Iso and Simone met for happy hour, where Iso convinced Simone to join the growing team. Simone graduated from the University of North Texas with a degree in operations management. She interned at Capital One throughout college and built a career across operations, process management, and customer insights strategy roles. During her college years, she started two hair businesses, one while in school and her second business once she graduated, which she ran for five years alongside building her career at Capital One. To finally bring her two career paths together, she decided to return to school and get her MBA at Wharton Business School. With a deep knowledge of the wig industry's product and customer experiences, coupled with formal customer insights strategy experience gained from Capital One and elite business skill building from Wharton, joining Parfait was a no-brainer for Simone. In her spare time, Simone watches after her daughter Kaia and takes her to dance classes where she is on a local majorette competition team—Simone is slowly becoming a dance mom. When the workday is over, you can catch her snuggled up with Kaia watching Disney's latest release or jamming out to some old-school R&B. Influencer & Brand Shout-Out: @swellabeauty “I can accomplish anything I put my mind to. If it's aligned to what God has called me to do and he told me, then I'm doing it.” Simone's Word of 2023: Parfait Tune in to learn more from Kendra and Simone!See omnystudio.com/listener for privacy information.
Russ Haddad, also known by his pen name A.A. Winston, is a man whose life journey has been coloured by a full spectrum of experiences, moulding him into the multi-faceted individual he is today. Born in Massachusetts, he was confronted with the loss of his father at the tender age of 12, a pivotal event that would shape his outlook on life and eventually inspire his poetic endeavours.Throughout his diverse professional career, Russ has explored various fields, showcasing his versatility and adaptability. Currently, he holds the role of Business Development Manager for the NC Craft Brewers Guild, where his passion for supporting local businesses and promoting the craft beer industry shines through.However, beyond the confines of his corporate life, Russ has always harboured a deep love for writing. This ardour was kindled during his high school days, and over time, it evolved into an emotional outlet through the medium of poetry. Serendipitously, during a crucial period of his life, the COVID pandemic, poetry came to the forefront once again, becoming a means of coping with life's challenges and uncertainties.Rediscovering the joy of putting pen to paper, Russ decided to share his poetic creations with the world. Through his verses, he artfully conveys his emotions, hoping that his experiences resonate with others and provide solace to those who find solace in his words.Today, Russ calls Chapel Hill, NC, his home, where he resides with his loving wife. Meanwhile, his son resides in the bustling city of Boston, a testament to the connections he has fostered with his family. When not engrossed in the art of poetic expression, Russ continues to explore the rich tapestry of life, ever ready to embrace new challenges and experiences.In the realm of poetry, business, and life, Russ Haddad embodies the spirit of a true Renaissance soul, using his words and actions to leave a lasting impact on those fortunate enough to encounter his work and his presence. Hosted on Acast. See acast.com/privacy for more information.
They say your twenties are meant for self-discovery and today's guest, Manila Mixtape, can attest to that. After a career in fashion bouncing from celebrity styling to merchandising to retail, Manila decided to walk away from it all. Knowing he needed a real break from that world, he moved back to NYC to become a truck driver. Serendipitously, his first assignment was to a fabrication studio. He'd work at the studio doing build outs for Vogue, Louis Vuitton and more. It was at the fabrication studio, Manila made his first mirror. In our chat ahead, we talk about his creative journey, taking the negatives with the positives to rebuild and launch his art as @ManilaMixtape.Co-Founder of Claima and Former Nike Marketer, Bimma Williams interviews leading and emerging creatives and entrepreneurs of color about how they were able to build their own tables by turning their hobbies, side hustles, and ideas into thriving small businesses. From these stories, listeners will learn how to claim their dream careers by stepping into the world of entrepreneurship. Featuring Melody Ehsani, Dapper Dan, Jeff Staple, Karleen Roy and more. Follow Claima Stories and Bimma Williams on Instagram: @claimastories and @bimmawilliamsAnd watch us Youtube powered by Vista. Vista is proud to be your go-to design and marketing partner for small business owners across the world. Use code CLAIMASTORIES at check-out on www.vistaprint.com to receive 20% off your next order of $75 or more plus free standard shipping.
There is an idea in psychology that "Radical Honesty" with one's self and those around you is an important key to health and happiness. Not just an idea, but a book and series of workshops on the idea, if you are interested. Serendipitously, Rabbi B. found this idea during a week where several of the clients I work with struggled with "honesty" in critical ways - and not just "lying", the lack of honesty, but in some ways, TOO MUCH honesty. So, B. and I decided to pepper this idea around and compare it to logotherapy's concept of "Response-ability", or, what we called, for today, "Radical Responsibility". Enjoy!And, if you want to read a little more in-depth about the cases I've referenced at above, I'll write a little more about them over at on my website, www.DanielAFranz.comTo find out more about what we have going on over at The Meaning Academy, go to: https://www.themeaningacademy.com/ To support your favorite podcast on Mental Health & Meaning, pick up some meaningful The Meaning Project Podcast merch in our store at https://the-meaning-project-podcast.creator-spring.com/And finally, if you would like to support our efforts to improve the podcast and maybe even connect with Dr. Dan in different ways, become a Patron on our Patreon page at: https://www.patreon.com/themeaningprojectpodcast
George Morris shares some key points on helping your business grow. Having a clear vision that all the players know and buy into are so critical. Plus having the right team members. George Morris Biography: As a certified Scaling Up coach, I collaborate with CEOs and founders to help align their leadership teams and optimize their energy and focus to achieve their company's objectives. Serendipitously, I discovered a role that perfectly harmonizes my passion, interests, and skills. Before embarking on this journey, I spent nearly 15 years as the owner of a digital agency, developing software and crafting marketing strategies for clients. My diverse experience also includes co-founding and managing one of the Top 10 TEDx organizations, leading the Entrepreneurs Organization in Colorado, and being part of the second physical product company to enter the prestigious Techstars venture incubator. My work brings me immense joy and satisfaction. I wholeheartedly embrace the concept that work and play are intertwined, creating a harmonious balance in my life. Contact Information George Morris-https://gmorris.com/ Benny Carreon- Velocity Technology Group- benny@velocitytechnology.group Dennis Jackson-WorX Solution- dennisj@worxsolution.com Music by: jorikbasov from Pixabay
Natasha Kaneva is joined by Gregory Shearer and Tracey Allen to discuss the exceptionally strong wintertime heat being observed across the Northern Hemisphere and its implication on the broader commodities complex. January forecasts of the Population Weighted Heating Degree Days index (PWHDD) for the Northern Hemisphere currently sit more than three standard deviations warmer than the 10-year mean, leading to swings in prices and pressures on fundamentals. At the same time, the team discusses the impact on commodities demand from an earlier than expected reopening of the Chinese economy. Speakers: Natasha Kaneva, Head of Global Oil and Commodities Research Greg Shearer, Head of Base and Precious Metals Research Tracey Allen, Head of Agriculture Research This podcast was recorded on 13 Jan 2023. This communication is provided for information purposes only. Institutional clients please visit www.jpmm.com/research/disclosures for important disclosures. © 2023 JPMorgan Chase & Co. All rights reserved.
Realizing that other players and guilds have progressed slightly further than AOD during their hiatus, our adventurers get caffeinated and get ready to head out. All while trying to figure out "what's a PUAZ?" Serendipitously this leads them into the sewers in an attempt to progress the main plot of floor 15.Be ready to spend your star points in Sword Art Online: AOD S4E18.Parental Note: Please be sure our content is appropriate for your family. We would rate it as PG-13 for content. About:Sword Art Online: AOD is an actual play podcast that follows the story of the "Antithesis of Darkness" guild on their journey to simply survive being trapped inside of an MMORPG world. This ain't your mommas' Sword Art Online. Now put on your nerve gear and prepare to shout "link start!"Want to talk more about the show or discuss your favorite episodes with the cast? Join us in our discord server or follow us on social media!Contact Us:Email: info@missingrollplayerfound.comFollow Us:Website: https://missingrollplayerfound.com/Linktree: https://linktr.ee/rollfoundSupport Us: Please consider contributing to the production of the podcast.Patreon: https://patreon.com/missingrollplayerfoundDice Envy (affiliate): https://diceenvy.com/?rfsn=2188188.53cb38Battlebards (affiliate): https://battlebards.com/#/register/mrpfpodMusic Attribution: Ivan Duch (Peaceful Tavern)Link: https://ivanduch.com/Michael Ghelfi (Steampunk City, Slums, Sunset Grove, Dark Metropolis Slums, Quiet Tavern)Link: https://www.youtube.com/user/MichaelGhelfiLicense: Used with permissionMonument Studios (Cold Atmosphere, Dark Slumber, Something in the Dark, Strange and Anxious)License: PurchasedMusic d20 (Eyes in the Fog (Sparse))Link: https://www.patreon.com/musicd20Battle Bards Olivier Girardot (Walking on Stone in Clothes, Walking on Stone in Leather Armor, Walking on Dirt in Clothes, Walking on Dirt in Leather Armor); Plate Mail Games (Ancient Forest Night, Ancient Forest 2 Night)Link: https://battlebards.com/#/register/mrpfpodOther Music and Sounds by Syrinscape Link: https://syrinscape.com/?att_missing_roll_player_found Because Epic Games Need Epic Sounds If you need music in your games check out our friends over at BattleBards. They provide the most premium audio library with over 3,400+ tracks including Musical Scores, Sound Effects, Soundscapes, and more! Support this podcast at — https://redcircle.com/missing-roll-player-found2852/donations
Welcome to the wonderful world of Sheri Scott, aka @foreveryoursbetty We are both longterm fans of this incredible creative's content, so we feel very lucky and incredibly grateful to have had a blether with this absolute tangerine dream! Glasgow's finest Sheri, is a multi-hyphenate - very appropriately nicknamed 'the ideas factory'. Her flame haired head hosts a brilliant brain constantly buzzing with brightly coloured ideas, which she uses to put the fire into businesses. From high fashion to chimpanzees, you name it and Sheri's unique and creative 'big picture' brain waves will catapult companies to flaming results. You've only got to take a quick glance at her own platform to see that this lady is a Queen amongst content creators! As the pandemic threw a spanner into the works the world over, Sheri's work and coping mechanisms shut down, just as Tik Tok began raising awareness about ADHD - opening her eyes to the neurodevelopmental disorder. In 2020 Sheri received a late ADHD diagnosis at the age of 34, and was referred for a screening for Autism, as she presents highly for this also. (We will further explore ASD in a furture episode)What followed was sadly nothing short of a frightening and dangerous ordeal!Without the essential support she should have been provided(!) Sheri has taken treatment into her own hands. She takes responsibility for managing her clashing ADHD and Autism symptoms, and has found what works for her. *We hear of many using ADHD medication in a way that works for them, but just in an attempt to be responsible (though being so isn't our strong point!) I'm sure all will understand that we have to say this - always read and follow medication instructions* We are so grateful to Sheri for sharing one hell of a ride on the late ADHD diagnosis rollercoaster with us! Her insight into 'NEURODIVERSE JOY' is so touching, that it's even giving me goosebumps now just thinking about it! We were so moved in her description of the joy that the colour orange brings her, that we've changed our signature colours, turning our socials orange for the week in her honour... WE'VE BEEN TANGOED! Serendipitously, orange is also the colour of ADHD Awareness Month, so we are very happy to be giving Sheri mega dopamine hits, whilst raising awareness for the cause at this important time. Further serendipitously, having been enamoured by Sheri being her striking citrus self unapologetically; we were hurt this week for being called - in a nutshell - 'too much'. We end this episode with a Reynolds rant(!) in which we acknowledge our need to educate ourselves about social media accessibility. We understand that we need to be mindful of that going forward; but taking the lead of Sheri, we outright refuse to dull our sparkle!We are loud, colourful, chaotic and busy-minded people who won't be to everyone's tastes; but after a lifetime of masking, authenticity is essential as we embark on this new chapter which we share for the cause. Our podcast and our platform are a reflection of ourselves and how ADHD presents in US. We take great inspiration from your authenticity, creativity and bravery, and therefore we are forever yours Sheri! *TRIGGER WARNING* There is some swearing, mentions of medication, misdiagnosis, malpractice, mental health crisis, financial struggles, and heart stabbing - metaphorically! Support the show
For those about to Burn! I have procrastinating my own packing for That Thing in the Desert by making you this compilation of my best Black Rock City conversations. From asking the Big Meow Marian whether Burning Man is a festival, to fumbling towards inclusivity with activist Nexus, from Burners without Borders to the Nordic Borderland, these are some of my favorite BRC moments from Life is a Festival. I've also added a few PSAs including how to talk to cops (Don't!), how to protect yourself and loved ones from fentanyl adulteration, and how to help someone having a difficult psychedelic experience. Serendipitously this journey also maps well to the 10 Principles, so you can beef up your cultural acumen on your way to the playa. May you pack all the things but waste nothing and I'll see you soon in the dust! GIFTING (:09) Caveat Magister (Burning Man Philosophical Center) Episode #28: What's the Point of Burning Man? https://www.eamonarmstrong.com/lifeisafestival/caveat-magister RADICAL SELF-RELIANCE (:17) Marian Goodell (The Burning Man Project) Episode #79: That One Time We Saved Burning Man https://www.eamonarmstrong.com/lifeisafestival/marian-goodell RADICAL SELF-EXPRESSION (:23) Adah Parris Episode #68: Visions of an Afropunk Futurist Parrishttps://www.eamonarmstrong.com/lifeisafestival/adah-parris CIVIC RESPONSIBILITY (:33) Gustaf Tadaa (The Borderland) Episode #2: Leaderless Leadership at the Nordic Burn https://www.eamonarmstrong.com/lifeisafestival/gustaftadaa SAFETY THIRD PSA (:40) How to Deal with Cops at Burning Man by Mark Atwood https://docs.google.com/document/d/1lFAWDVzbRLkTM43Y588-ffFxuH7BfXzFbQ8ms7XF_xw/edit HARM REDUCTION PSA (:51) Mitchell Gomez (Dancesafe) Episode #120: In the Age of Fentanyl, Test Your Drugs! https://www.eamonarmstrong.com/lifeisafestival/mitchell-gomez IMMEDIACY (1:00) Sara Gael (The Zendo Project) Episode #51: How to Help Someone Having a “Bad Trip" https://www.eamonarmstrong.com/lifeisafestival/sara-gael RADICAL INCLUSION (1:10) JR Nexus Russ Episode #32 Fumbling Towards Inclusivity https://www.eamonarmstrong.com/lifeisafestival/nexus DECOMMODIFICATION (1:15) Ashoka Finley Episode #83: Power & Privilege in Intentional Communities https://www.eamonarmstrong.com/lifeisafestival/ashoka-finley LEAVING NO TRACE (1:23) Jamie Wheal (Stealing Fire) Episode #80: Live From the Infinite Playa https://www.eamonarmstrong.com/lifeisafestival/infinite-playa COMMUNAL EFFORT (1:33) Christopher Breedlove (Burners Without Borders) Episode #50: Serve in the Way that Feeds You Most https://www.eamonarmstrong.com/lifeisafestival/christopher-breedlove PARTICIPATION (1:41) Life from BMIR (Burning Man Information Radio) Episode #29 It's Better With You Here | Life is a Festival #29: Live From BMIR https://www.eamonarmstrong.com/lifeisafestival/bmir
Mercy Bell's relationship with alcohol started in college as a way to thwart the uneasiness she felt inside. It led her to a “recovery or else” situation. She used multiple paths and experiences along her journey to recovery. Today, Mercy is the co-owner of Sober Voices and Sourcing Voices, with Alyssa Hart. Their mission is “to amplify and celebrate all voices and all experiences on the journey of recovery and mental health”, especially college students, LGBTQ+, and BIPOC. In this podcast, Mercy talks about: Having a “high bottom” that most people couldn't see and using many paths to recovery Serendipitously meeting Alyssa Hart who was creating an online sober event, FLOW Being a “buffet grazer” of recovery Being impressed with the technology and ecosystem Alyssa was using for a grassroots style recovery movement during the pandemic The inspiration to start Sober Voices for online recovery events and Sourcing Voices, the technology platform where recovery content lives Why having a diversity of voices and stories is key to having people relate and connect The mission of Sober Voices and why they chose to use the words Amplify and Celebrate Finding SMART while planning for FLOW 2021 The future goals for Sober Voices and Sourcing Voices
Producing graffiti and street art on the streets as well as in the digital realm, Diego Bergia is doing graf work you've probably never imagined existed. If you've played Tony Hawk's latest video game, you'll see Diego's graffiti all over the game. Serendipitously, he's become the guy that people go to to place graffiti into digital spaces. On this episode, Diego talks about how natural his career has been and how his lifelong love of animation, graffiti and arcade games merged together into the most NFT perfect project before NFTs even came into his consciousness. Diego Bergia online: https://www.instagram.com/diego_bergia/ https://linktr.ee/diego_bergia https://opensea.io/collection/throwiez Podcast producer and sponsor links: https://www.totemo.art/ https://www.instagram.com/totemo.art/ https://www.instagram.com/splatrsart/
Looking for steps to uncover your niche? Save yourself some time and get 20 years of experience, condensed to 7 steps. Available now on Amazon: Dream Octane: Seven Steps To Discover, Develop and Deliver Your Niche: https://www.amazon.com/gp/aw/d/1795308478/ref=dbs_a_w_dp_1795308478
Have you wondered how you could share the consciousness shifting with younger generations? How could you explain the infinite possibilities available to each of us through understanding our thoughts and feelings to create our own reality? In this week's Light Up Your Worth podcast host Debbie McAllister talks with co-authors, Phoenix Rose and Sara Anne Noah, of The Grass is Always Greenest Under Our Own Feet. The Grass is Always Greenest Under Our Own Feet is the transformative and metaphysical journey of two superhero teenagers, Synchronicity and Serendipity Heavenridge, who come from the town of Starseed, a Utopian village where everyone's aura shines brightly an the grass is always green under their feet. The intuitively gifted siblings answer a call for help to go on a divine mission to the town of Lost Valley, a place caught up in the trauma and drama of the old paradigm of lack and limitations. There, they explore the experience concepts foreign to them, such as fear, illness, doom, greed, racism, polluted air and water; scarcity, and lack of compassion. Ultimately, they help to uplift, heal, transform and shift the lower vibrations of the townspeople into unconditional love consciousness before it's too late. Co-authors, Phoenix Duffy and Sara Anne Noah were both born and raised in Southeastern Michigan but did not know of each other. Serendipitously, they both arrived in Northern California in the summer of 2016 and met in the East Bay at a spiritual center called The Home Of Truth. Entertained and moved by observations of magical events that they experienced together in California during their blossoming friendship, they became inspired to write this allegorical storybook, a tale of hope and redemption. More recently, Sara & Phoenix both moved back to Michigan and are excited to explore animation scripts and movies involved with their book. To reach Phoenix and Sara Anne: Website to order: Thegrassisalwaysgreenest.com Facebook: The Grass Is Always Greenest Under Our Own Feet Book Fans Instagram: thegrassisalwaysgreenest YouTube: Thriving in 5D https://www.youtube.com/channel/UCxYe1XrOxwRWA-ZxwBZhFuw Looking to support and contribute to raising the consciousness and empowering women: Buy Me A Coffee https://www.buymeacoffee.com/lightupyrworth Debbie McAllister is a Spiritual Transformational Coach and Light Up Your Worth podcast host. Debbie offers recorded energetic healing meditations to clear out the limiting subconscious beliefs, and self-sabotage patterns, & release negative habits, interrupt & healing generational trauma, and lovingly guide you through the process of transition. Free Quick Confidence Boosting Meditation at her website https://www.lightupyourworth.net Instagram: https://www.instagram.com/lightupyourworth Facebook: https://www.facebook.com/groups/LightUpYourWorthCommunity/ YouTube: https://www.youtube.com/channel/UCQwejn7z8iZ36X-eBPx199g Debbie shares: Sage Essential Oils and Reiki with Niki Thomson. She can be reached at https://www.instagram.com/sage_essentialoils/ The Badass Book Besties Book club is dedicated to transforming the lives of women. https://badassbookbesties.com --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/lightupyourworth/message Support this podcast: https://anchor.fm/lightupyourworth/support
Episode 55 of The Far Middle is dedicated to a sports record—Wilt Chamberlain’s 55 rebounds against the Celtics on Nov. 24, 1960. Nick reflects on the career of Chamberlain who maintains the NBA’s record of 23,924 rebounds, and notes Bill Russell is number two at just over 21,000 boards, followed by Kareem Abdul-Jabbar at 17,440. Serendipitously, Bill Russell played against Chamberlain in that 1960 rebound record-breaking game.Following his comments on the career of Chamberlain, which came about due to his massive potential, Nick addresses the massive potential of Appalachian energy. He juxtaposes his “sadness” mentioned in episode 54 regarding energy policy with excitement if America gets energy policy right and Appalachia energy is allowed to be unleashed. He further explains the key differentiator of free market versus government control when it comes to energy.“When government gets involved in complicated matters best left to the competitive free market of entrepreneurs and innovators to figure out, I can assure you bad things are always going to happen,” says Nick as he transitions to analyzing the government creating a monopoly for baby formula producers and government’s role in producing the recent formula shortage.While on the topic of government ineptitude, he looks at the over and undercounting in the latest Census. He also examines recent real estate purchases by the elites within the server class and closes by honoring the raw talent of the late Ray Liotta.
Today we're back with some more letter themed topics. We discuss different words that start with 'S' and of course as always, it get's a bit random as our conversation goes on. Hope you enjoy this episode!
3.00" Colette Twomey, founder of Clonakilty Black Pudding talks about her new project, her own golf club. As you do. She was trained as a brain technician but married a butcher which led to what is now a worldwide Irish food brand, known from Clonakilty to Sydney, Australia.She explains how a Dunnes Stores tea lady led to their hugely successful 'gluten free' range. She talks about producing 'white label' black pudding for other butchers.She gives a history lesson about the rise of supermarket multiples and what it meant for the Clonakilty business.Colette talks about how hard she worked, traversing the back roads of West Cork.She and her late husband, Edward, never wrote down a business plan but they had a vision. That was 'we love the pudding so much we'd like if people could buy it wherever they live'.The story of how they expanded into Australia is very revealing.She also reveals her plans for the US and for the soon to be launched vegetarian puddings.And she explains why it's all about attitude.She was a finalist in the EY Entrepreneur of the Year competition which she says gave her 'global vision'.Her 'hire in a heartbeat'? She chose a few - Norah Casey and Paula FitzSimons42.00" Kevin Maughan, CEO, Urban Volt talks about solar energy as a service. Serendipitously the EU has just announced a big move for Europe to move away from Russian fossil fuels.Curiously Ireland has a lot of daylight, which is all that is needed to make solar energy viable. But Urban Volt also has its fingers in another ten international markets.He talks about the 'battery first' future where businesses will produce their own solar energy and then store it in their own batteries.He mentions a perceived conflict of interest where State led utilities may be causing distortions in the energy market.His 'hire in a heartbeat' - Shane Lanigan of Beach Point CapitalThe great insights on That Great Business are made possible through the support of De Facto Shaving Oil Hosted on Acast. See acast.com/privacy for more information.
A groundbreaking study on redlining in the city of Pittsfield shows that this community was not immune to the discriminatory practices in housing and banking for people of color, particularly for African Americans, although, not limited to African Americans. The study was presented by the NAACP, Berkshire County Branch in April 2022. You can hear the audio version of the presentation here, along with a story by WAMC-Northeast Public Radio. I had the opportunity to speak to two individuals intimately involved in this research, including Dr. Frances Jones-Sneed – who spearheaded much of this work years back. In addition, community advocate and historian Kamaar Taliaferro shares some very specific anecdotes from his thorough research on one particular neighborhood that was not only impacted by redlining but essentially obliterated by urban renewal in West Pittsfield. Serendipitously, as the report was being finalized, a once mythical redlining map in Pittsfield was discovered in the National Archives. That's where we begin the conversation with Dr. Jones-Sneed. Frances Jones-Sneed is a professor of history (Ph.D., University of Missouri) and former Director of Women Studies at Massachusetts College of Liberal Arts in North Adams, Massachusetts. Jones-Sneed has taught and researched local history for over twenty-five years. She directed three National Endowment for the Humanities (NEH) grants entitled “The Shaping Role of Place in African American Biography” in 2006 and “Of Migrations and Renaissances: Harlem/NY & South Side/Chicago, 1915–75” in 2008, and "African American Biography" on 2011, all “We the People” projects. She spearheaded a national conference on African American biography in September 2006, is co-director of the Upper Housatonic Valley African American Heritage Trail, a former board member of MassHumanities, and is presently a member of the Samuel Harrison Society. She was a 2008 NEH Summer Fellow at the W. E. B. Du Bois Institute at Harvard University and is currently editing the autobiography of a 19th century local minister, Samuel Harrison and working on a monograph about W.E.B. Du Bois. Kamaar Taliaferro is a lifelong resident of Pittsfield, Ma. born and raised in subsidized housing. He graduated from Pittsfield High School in 2011 and was awarded a Christian A. Herter Memorial Scholarship, and attended Williams College from 2011 to 2014. I provided editing, analysis, and writing for the 2020 Black Economic Council's Idea Jam Success Report. Kamaar is a co-steward of Growing Legends–a project which seeks to develop an Urban Nursery and Youth Forestry Corp in Pittsfield and to inform new ways of communal gathering and collaborating utilizing art and gardening. In 2021 and early 2022, he was a fellow lead researcher on a case study of the Westside neighborhood in Pittsfield, examining the historical record for the presence, and investigating the ongoing effects of redlining in New England's mill towns. Currently, Kamaar chairs the standing committee on Housing for the NAACP, Berkshire County Branch, and is one of a growing handful of Farmers of Color in Berkshire County. You can often find me in Pittsfield at his urban farm tending to and being tended by the earth. --- Support this podcast: https://anchor.fm/john-krol/support
The Glass Art Society (GAS), Inc. is an international organization whose mission is to encourage excellence, to advance education, to promote the development and appreciation of the glass arts, and to support the worldwide community of artists who work with glass. Since 1971, GAS has been using the joy of glass to connect, inspire, and empower all facets of the global glass community. From the early days of the American Studio Glass movement to the upcoming United Nations' International Year of Glass, GAS continues to foster connections that last a lifetime. This year's gathering – held in Tacoma, Washington, from May 18 – 21 – celebrates 50 years of Glass Art Society. With the theme Between Here and There, this milestone conference will explore the past five decades of glass and what the next five decades will hold for making, collecting, and educating. GAS Executive Director, Brandi Clark, says: “This will be one of the most exciting GAS conferences yet. GAS will be celebrating its 50th Anniversary, it is the United Nations' International Year of Glass, and we will be able to gather together again after three long years! While celebrating the history of GAS, we will also be highlighting the reach and diversity that is the future of the glass community. Our Saxe Emerging Artists are a great reflection of that.” The Glass Art Society is pleased to announce the 2022 Saxe Emerging Artist Award recipients: Fumi Amano, Krista Israel, and Madeline Rile Smith. Each winner will receive the opportunity to present at the 2022 Annual GAS Conference, placement in a digital artist exhibition, an honorarium to support their artistic endeavors, and more. Through a competitive jurying process, GAS recognizes emerging artists every year based on their promising talent with glass. Applicants—nominated by peers, academics, and curators—are evaluated by a professional panel of jurors. All interdisciplinary artists, each of the three winners use their work to explore the similarities between the unique properties of glass and their own minds and bodies. Joining me on this episode of Talking Out Your Glass podcast, Smith uses glass as a “performative vehicle to consider notions of intimacy and embodiment,” exploring the parallels between the human body and the medium of glass. Informed by her background in music, Smith creates objects that explore connection and isolation. Her work has been exhibited in venues throughout the US and internationally, and has been featured in New Glass Review 41 and 35. She currently teaches glass art as an adjunct professor at Rochester Institute of Technology and has instructed glass working in schools and institutions throughout the East Coast, including UrbanGlass, Salem Community College, and the Crefeld School. You can see more of her current work and educational videos on Instagram, Youtube, and TikTok. States Smith: “Informed by my experience with chronic pain, my work explores degrees of ability and compromise of the human body. Pain has caused periods of isolation in my life, and as a result I have a strong impulse to connect with others. I utilize glass as a performative vehicle to explore interaction between people. Through objects and performance, I examine the pleasure, intimacy and discomfort that accompany the interpersonal experiences we all seek.” This episode also features a conversation Natali Rodrigues, former GAS Board President, this year's GAS Lifetime Membership award winner, and Associate Professor in the Glass Program at the Alberta University of the Arts in Canada. Rodrigues discusses the upcoming GAS conference, the organization's new mission, vision, values and strategic plan, and how those are being implemented to create a more inclusive organization and glass community. “The more work GAS does to be an international organization, the more ways it finds to bring together the glass community across borders,” Rodrigues says. And you'll hear from one of GAS' founders, Fritz Dreisbach. Equal parts artist, scientist, and historian, Dreisbach has spent the last five decades teaching and demonstrating glassblowing around the world. This “Johnny Appleseed of Glass” has himself played a vital role in the history of the American Studio Glass movement that he now strives to preserve and share with the next generation. In the process of inspiring others to try glass, Dreisbach began studying and reinventing historic shapes in glass with his personal brand of irony, humor, and fun. Children's toys and games, funk ceramics, and 1960s comics all inspired Dreisbach's early artwork. Above all, he endeavored to capture the fluid nature of the hot glass used to create his work. Having studied painting at the University of Iowa, earning his master of arts degree, Dreisbach planned to eventually teach college level art, thus his advisor instructed him to study a wide variety of mediums. A two-credit, experimental course in glassblowing was part of the curriculum. Serendipitously, his love affair with glass began the summer of 1964, only two years after the seminal '62 Toledo Museum of Art (TMA) workshops. During this time, Dreisbach first met and was inspired by three pioneers of Studio Glass—Harvey Littleton, Dominick Labino, and Erwin Eisch. Dreisbach has led hundreds of workshops and lectures about glass in over 185 institutions worldwide. Traversing the country, teaching and spreading the gospel, earned him the moniker, “The Johnny Appleseed of Glass.” Dreisbach designed and built many hot shops in the 1960s and 1970s, including Pilchuck Glass School. After his short visit in 1971, the artist began teaching and advising the school for over four decades and has served as an artist trustee since 1993. He helped found and direct the Glass Art Society, which presented him with its Lifetime Achievement Award in 2002. Enjoy this multi-faceted conversation about GAS – past, present and future.
We're covering one of cinema's heavy hitters this week, as we cover the masterpiece that is The Godfather. Serendipitously this year is also the 50th anniversary of the film, so it's the perfect time to geek out about it. We talk about what makes this film work so well, from it's technical filmmaking to its perfect storytelling. Join us for a fun conversation on this cinema classic. Contact us at rollitpodcast@gmail.com or follow us! Twitter - @RollItPodcast Instagram - @rollitpodcast Music by Ethan Rapp
To help continue the much-needed support for the people of Ukraine, we have produced a compilation from one of our favorite Ukrainian-based netlabels, Energostatic Records. Released as part of our Portals deep dive series, the feature includes a remaster of specifically curated tracks, in both individual and mix form. These tracks are available on the ASIP Bandcamp page as Name Your Price, with all proceeds going to Save The Children and their specific activities supporting Ukraine at this time. A big thank you to label owner Marian for allowing this project to happen as he deals with life in Kyiv right now, the artists for their participation, and Rafael Anton Irisarri for kindly providing his mastering services. Also, an advanced thank you to all those who listen and support at this very important time. ~‘Netlabels' are essentially extinct in today's music landscape by definition. Of course, there are still labels that just focus on digital releases, but Netlabels came about during a time when there were little to no platforms monetizing digital releases. Digital distributors were reserved for big or established labels as the streaming era ramped up. And Bandcamp didn't exist. Netlabels were the next logical step after the file-sharing era (Soulseek et al), where instead of P2P servers and software, artists and label began to push their own agendas online, making files available freely on the internet, often under a Creative Commons license and many through a myriad of MP3 blogs that powered this exciting period. It was also, somewhere at this point in time, coincidentally, that the very first iteration of ASIP was also born, diving deep into MP3 blogs and following various Netlabels religiously. Finding a Netlabel's basic website or archive.org page was the Bandcamp profile of its day. Energostatic was pretty late to the ‘Netlabel game'. Their first release didn't arrive until 2010 when many Netlabels were either fizzing out already or converting to more modern release methods. But Energostatic's ethos and approach to providing music against a strict aesthetic, for free, made them a torchbearer for the dying art of sharing music online through small yet beloved corners of the internet. As ASIP began in 2008, Energostatic was one of the many Netlabels I followed, and as curators of dub techno in various forms, they operated within another small yet burgeoning scene it seems, given dub-techno as a genre also seems to have dwindled in popularity in recent years. The writing was perhaps, on the cards for Energostatic, as Marian ceased operations of the label in 2017. But with 49 releases, there was (and still is) a big chunk of music to dig into, which for anybody new to the label, could become a little overwhelming to discover, especially since that number includes several compilations with 20+ tracks each, and many of the artists don't seem to be very active anymore. To help support the people of Ukraine during this time in a small way, I reached out to label founder Marian to see if he would like to raise money through a compilation that spotlighted some of my favorite music from the label's era. Marian had previously released as part of our early Places Series, as Marc Atmost, where he created a track based on some of his early memories in Ukraine (an unsettling and poignant listen under today's circumstances). Today, Marian is on the ground in Kyiv, doing what he can to survive and support his community.The majority of the Energostatic catalog is still available for free on Bandcamp, should you wish to explore it yourself. Ranging from Space Ambient to drone; dub-techno and DnB; it became a bittersweet task to sift through the hundreds of tracks and pull together this compilation for a good cause. With the owner and label based in Ukraine (if Netlabels were to even have a ‘base' of course), the majority of the artists on the label were friends of Marian, so a good majority were Ukraine and Russia-based and a part of local music scenes in each country. The compilation begins with one of the most gentle tracks you will find across the entire Energostatic catalog. Russian artist KaLGaN made a few appearances over the years, but was better known for his work as 110ml - responsible for the very first artist release on the label (Scratch me / Scratch you) and also included further on in the compilation with his 110ml track, Lights In Window. Stellardrone (Lithuania), is one of the more well-known artists to be supported by Energostatic, and even made an appearance on the ASIP Full Circle compilation/LP a few years back, highlighting his importance in the evolution of my own musical journey. Edgaras' music has always remained free on the internet and encaptures some of the finest Space ambient music in recent years. The piece included in the compilation, ‘Light Years' is perhaps one of his darker, more sincere pieces amongst a stand-out catalog which has unfortunately not seen much activity in recent years Textural Being (USA) (see isolatedmix29 also) is another artist who I have admired for a long time, and related to the above compilation was in my shortlist for inclusion on Full Circle. The track I had in mind at the time, however, didn't quite fit the rest of the compilation. Serendipitously, Sept is my all-time favorite track by Sage Taylor / Textural Being, (amongst yet another expansive artist output) so it feels great to present this to a wider audience today. Marc Atmost (Ukraine), as mentioned above, is the founder of Energostatic, and appears consistently across the label over the years through various guises and musical styles ranging from straight-up dub techno to DnB. This track, Deity is one of my favorites from his consistent output, capturing the very essence of spacious, melodic dub techno. Olexa, (Ukraine) was a less prolific artist over the years with just one EP and several compilation appearances on Energostatic, but captured the deep dub techno sound aesthetic of the label to perfection. Gapfield (USA), is a project from US-based Devin Underwood and Jacob Newman. Devin creates some amazing music across a variety of styles and aliases (such as Drexon Field - another fun project I love) and has made several appearances on the Energostatic label, most notably with a solid, straight-up dub-techno album as Specta Ciera (see isolatedmix19). Between Devin and Jacob, they can be found on some amazing ambient labels over the years, such as Carpe Sonum, Neotantra, dataObscura and Bludhoney Records. Their Gapfield project, is definitely one that may have flown under the radar amongst their solid output. Technicolour's (UK) ‘Permafrost', has always been a stand-out track for me on Energostatic and his only appearance on the label. I included it in many of my DJ mixes years ago, and it broke the mold in the label's beginnings with its Autonomic sound and rampant amen breaks, whilst remaining true to the deep and introspective atmosphere the label ended up pushing. But it wasn't until seeking permission to include this track did I come to realize that Technicolour, aka Peter Rogers, was in fact, Wardown, who released one of my favorite Drum'n bass albums of 2020 on Blu Mar Ten's label. Permafrost could be the apex of compilation, but the journey needed a minute to breathe after that kind of energy, which is where Ayqix's (Argentina) Raymi (Coldest Version) came into play. The Buenos Aires musician provides an airy respite towards the end of the compilation before the energetic finale, very much reminiscent of the early minimal techno days of Traum Schallplatten. Closing out the compilation, Enformig, was a Ukrainian Techno producer based in Kharkov who unfortunately died in 2019. His appearances on the label were always met with such high praise and support on social media from Marc, especially for his hardware-driven live sets. This track is perhaps, one of his finest moments from the Energostatic catalog and provides a momentous, energetic and liberating closing chapter to the compilation. Energostatic's label motto was "Reach, resist, research”. Label owner Marian didn't have the time or capacity to answer any of my questions related to its meaning on top of his urgent life on the ground in Kyiv, but I couldn't help relate this motto to a higher meaning and reminder as I thought about his and many other people's lives in Ukraine. Thank you for reading, listening and reflecting. Support the compilation on Bandcamp with all proceeds going to Save The Children and their Ukraine efforts. Portals: Energostatic (For Ukraine) by A Strangely Isolated Place~Podcast link.
My human conversation today is with the lovely Alison Taylor. Here is a little bit about her... A professional network marketer with Forever Living Products since 2006, Alison is also a qualified health and nutrition coach and with over 35 years teaching, she is passionate about health and wellbeing. What brings her joy is enabling, educating and supporting others to help us all live our best lives. Our conversation covered a few of those serendipitous moments in her life - of which there have been a few!
Equipped with a law degree, an internship from the BBC White City in TV script writing and film production, plus certification as an ESL teacher, and still only in her 20s, Zoe Popham headed for Thailand for adventure, and to teach English. Serendipitously, she knew an English guy working in Bangkok on a film and he invited her to work with him. The realization that there was international production work in Thailand, led to a job opportunity with an Indian-Thai production company that made TV commercials for India. Over the next 18 years, Zoe worked her way up in the industry, but after a nearly 2-decade career in Asian TV commercial, news and feature film production and post-production, in 2015 she relocated to Portugal in search of a more balanced and healthy lifestyle for herself, and her young son.
We all remember the royal wedding of Prince Harry to the American actress, Meghan Markle, in 2018. I remember getting up early to watch it streamed live as I know many Americans did. Serendipitously, a classical cellist performed in the ceremony that day to a global audience of 2 billion people, in St. George's Chapel at Windsor Castle. That cellist, Sheku Kanneh-Mason, has since charted a meteoric rise to prominence. This month, he makes his New York Philharmonic debut. He's also just released an album with his sister, the brilliant pianist Isata Kanneh-Mason. Both Sheku and Isata join me on the Classical Post podcast today to discuss this new album called Muse, released on the Decca Classics label, featuring gorgeous works by Rachmaninoff and Barber. Listen to this discussion about how these siblings create art together. But also, hear a brief snapshot into Sheku's New York Philharmonic debut and what it was like for him performing at the royal wedding. -- Classical Post explores the intersection of classical music, style, and wellness, diving into meaningful conversations with leading artists from an array of different backgrounds. Based in New York City, Classical Post is a touchpoint for tastemakers. Visit our website for exclusive articles or subscribe to our monthly newsletter to be notified of new content. Follow us on Instagram, Twitter, or Facebook.
Bass-baritone Dashon Burton joins us on the Classical Post Podcast to discuss style, wellness, and his successful career that won him Grammy Awards. Serendipitously, we actually recorded this interview two days before he won the second Grammy for his work on Smyth: The Prison. Here are some highlights of what we discussed on the podcast. Style icons: Thundercat, Amy Sedaris Dream home: At least a Tesla in the driveway. The aesthetic should also be one that connects people and draws people together. Style philosophy: Style is about inviting people into your community. Product recommendation: You Need a Budget (YNAB), the Marie Kondo of budgeting. Guilty pleasure: "…nothing wrong with RuPaul's Drag Race.” What energizes him: Connecting with students who don't normally have access to classical music, as well as anyone who's curious to learn more in life. How does he define success: Success is feeling comfortable in your own shoes. Greatest career moment: Attending the Grammy Awards ceremony with his mother and sharing that success of winning with her. Learn more: dashonburton.com Remember to follow Classical Post on Instagram and Facebook. Visit our website with insightful content on classical music, style, and wellness. Hit the subscribe button wherever you're listening to this podcast to be notified of new episodes!
Pharaoh Kyle is an incredible spiritual and nutrition coach, who is a testament to the power of intention. After facing a crushing blow in 2011, Kyle happened to see a Will Smith video where he was praising the international literary phenomenon of The Alchemist. Serendipitously acquiring a copy, the message of following your soul's calling resonated with Kyle, and he began the process of looking inward. Harnessing the power of fasting, Kyle gained clarity and insight into his own unfathomable ability to create change in his life. He reached his goal of making a million dollars by 30, and is now dedicated to helping people around the world wake up to their innate strength and worth. Tune in to hear details of his journey, his go-to morning routine, and all of the synchronicities that occurred once he made the decision to follow his intuition . Check him out on instagram: @ pharaoh333And read up on some of his articles: https://www.yahoo.com/now/pharaoh-kyle-better-known-pharaoh-233500130.htmlI deeply apologize for the sound issue on my end of the podcast! I'm still figuring things out, but the good news is there's nowhere to go but up from here! Luckily Pharaoh does most of the speaking, and if you stick along for the ride, I promise there's magic in Pharaoh's words.
Episode 2 Language: English Magnolia brings a very special guest from her circle: Anneli Marceles; Mamá, Esposa, Latina Empowerment coach
How can artists create their own luck and meaningful accidents and also make accidents meaningful? How can a serendipity mindset, transform the culture and the way we deal with life and everyday events. Dr. Christian Busch in his wonderful book- THE SERENDIPITY MINDSET- encourages us to cultivate, nudge serendipity for a better and quality-driven life. This book has been endorsed by Arianna Huffington of the Huffington Post and Reid Hoffman founder Linkedin. We talk: 1) Serendipity vs Synchronicity 2) Hustling culture vs the serendipity culture. 3) How can artists specifically cultivate a serendipity mindset and what can come from it. 4)The Hook Strategy- let others connect the dots for you and let you connect the dots for others. 5) Serendipity mindset to overcome biases and behavioral changes 6) Who are your role models and why we need to look at them? 7) Nudging towards serendipity as we move towards the unknown in this profession..- 8)Tracking serendipity daily. Shades of Spring by Kevin MacLeod Link: https://incompetech.filmmusic.io/song/4342-shades-of-spring License: https://filmmusic.io/standard-license The Artists is a self-funded podcast, if the information and has helped you consider supporting us. Consider supporting us with the amount you choose that can help us in our basic operations! https://www.eplog.media/theartists/season-2/e67/ Email id: metaphysicallab@gmail.com/ You can follow us and leave us feedback on Facebook, Instagram, and Twitter @eplogmedia, For partnerships/queries send you can send us an email at bonjour@eplog.media. See omnystudio.com/listener for privacy information.
Amy Risley feels that she has always been an entrepreneur at heart. Because her father worked in manufacturing for Estée Lauder, she became obsessed with all of the "lotions and potions" he brought home during her childhood. She also met Estée Lauder when she was five — and according to Amy, seeing a woman in such a powerful role left a lasting impression. After graduating from Princeton and spending years doing marketing for beauty companies like L'Oréal, Estée Lauder and Jo Malone, Amy became a stay-at-home mom — although she knew she'd eventually return to work one day. Serendipitously, she met the woman who owned the recipe for Skinfix balm, which ignited Amy's entrepreneurial spark. Amy read customer testimonials from people who tried tons of outlandish remedies for serious skin issues, from diabetic foot ulcers to psoriasis; they claimed this healing balm helped alleviate their symptoms and enhanced their quality of life. After seeing these reports, Amy was 100% in. The first order of business was to update the branding and create a highly targeted message. "When something does everything, it does nothing," Amy says. She took the brand from being an "everything balm" to focusing on eczema.Amy knew Skinfix would be taking on major players like Aveeno and Cetaphil in the eczema category but she felt ready for it. This may have been a bit naive, but "I think you have to be naive and sort of a dreamer to really survive as an entrepreneur," Amy says. Landing an early partnership with Target was crucial for Skinfix's brand development and ultimate success. Target helped nurture the indie brand, providing guidance on what was important for its target market, such as being dermatologist-recommended and clinically proven. From $100,000 in annual revenue to being carried exclusively by Sephora, Amy built a company that challenges household name beauty brands. She'll never stop giving consumers "what they want and what they need at the right price, and delivering a solution that's actually going to help."##Featured Challenger
Smart Objects had been on my radar for YEARS before finally seeing them at Exit/In sometime in 2018. It was exactly what I was hoping for - an angular pop/rock project that was suave, smart, deft and adventurous all in one. It didn't take long for me to get into talks with Ben Harper, who helms the project, where we began exchanging ideas here and there. Serendipitously, I was assigned randomly to cover one of his songs as part of the Nashville Song Swap, where Nashville bands were all tasked with the same challenge. I covered his song "Die Tonight" which was hella fun, and you can hear it at the end of this podcast. Enjoy!
Whether it be music, art, writing, or in this case, acting, everyone strives for that breakout moment. Serendipitously, Austin met with English actor Chris Webster right after he might have experienced that critical moment. What followed was a conversation on fame, chasing the ephemeral, giving up, moving forward, and the ins-and-outs of the LA acting industry. Mr Webster's alluring accent doesn't hurt, either. Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.
Gustavo Fernández's first career in pharmaceutical sales was inspired by his stepfather, who was the general manager for Johnson & Johnson in the Dominican Republic. Gustavo stayed in the industry for 10 years after graduating college — until his real passion started calling to him. Photography had been Gustavo's hobby since college. Wherever he went, he always took a camera along with him. Then, when the internet became a massive tool for building communities, he started connecting with other photographers. Serendipitously, one of the top wedding photographers in the world lived just down the street from him. So he went to a workshop she was holding, and that changed the whole trajectory of his life. Now, Gustavo has a career photographing people like Bill Gates and Warren Buffett. The internet and online communities continue to be hugely important to Gustavo's photography and career, too. Because, in this era of social media, the vast majority of new business that comes to him is through word of mouth. But you can't just be part of a Facebook group and reap the benefits of belonging to a community — you have to create lasting, authentic relationships with people When Gustavo is building relationships... He always follows up leads and conversations (he even carries a notebook so he doesn't forget anything!) He always picks up the phone. A couple of years ago the event planner for Forbes called to ask him to photograph an event. And she told him, Thank you for picking up the phone. No-one picks up the phone anymore. He gives unique, thoughtful gifts to clients and contacts. A $10 gift he sent to a contact actually resulted in $10,000 worth of business. Gustavo says that people sometimes comment about how different his two careers are but, at the end of the day, it's all the same — because “it's all people.” Don't be a podcast junkie… Resources: Gustavofernandez.com Instagram: @gustavofernandez Facebook: @gustavofernandezphotographer Twitter: @gustavo Read: Never Eat Alone Read: Into Thin Air Get your copy of Master the Key: A Story to Free Your Potential, Find Meaning and Live Life on Purpose -- We are brought to you by the Lawton Marketing Group, a full-service advertising and design agency serving companies and entrepreneurs at all levels. They are your one-stop shop for all your website, logo, social media, print, app design and reputable management needs. Visit LawtonMG.com for more info. -- The Impact Entrepreneur Show is a production of Crate Media
[0:00 – 1:56] Intro [1:57 – 4:27] Growing up in non-starstudded Ohio and discovering his drawing talents. [4:28 – 7:20] Serendipitously stumbling on the book “Aim High for a Career in Graphic Design / Art by S. Neil Fujita” at age 14 and starting art as a vocational trade. [7:21 – 12:10] The benefits of social ineptitude and the nerve to push yourself creatively. [12:10 – 17:57] The curse of ‘knowing the rules.' [17:58 – 26:16] For the love of rules and parameters. [26:17 – 28:16] Helvetica and 70's font style at the University of Cincinnati [28:17 – 33:35] The magnetic pull to New York City and working with mastermind Massimo Vignelli. [33:36 – 36:10] The healthy side of a workaholic. [36:11 – 38:16] Wisdom gained from 10 years with Vignelli and the importance of compelling ideas. [38:17 – 43:08] Leaving Vignelli to become a partner at Pentagram in 1990. [43:09 – 48: ] Working on the top-secret Hillary Clinton campaign logo. [52:49 – 54:59] Outro
Time for Fan Mail Friday, where we'll be answering your questions and dropping some knowledge and feedback to help you kick the weekend off right! In this episode: If high school and college didn't give you the best years of your life, it just means "the good old days" are probably still ahead. Are you lazy, disenchanted by a lack of challenges, or just afraid to fail? Have you considered the merits of self-deprecation? Criticism loses its potential for being constructive if it's not specific enough. Will your actions make the boat go faster? Relationships in the age of social media can be tricky, as we talked about in FMF 102. Did you know that Facebook has breakup tools? Jennie has a brilliant tip for people who are running late. Wasted potential is depressing. Quick shoutouts to Andrew Byrne and Jordan Laverty! Have any questions, comments, or stories you'd like to share with us? Drop us a line at friday@theartofcharm.com! Check out Jordan's other show: The Forbes List, and Jason's other show: Grumpy Old Geeks. What's the art of mastering the nap? Check out the Ben Greenfield Fitness Podcast here once you're done hitting the snooze button for the 17th time! Does your business have an Internet presence? Now save a whopping 50% on new webhosting packages here with HostGator by using coupon code CHARM! Find out more about the team who makes The Art of Charm podcast here! Show notes at http://theartofcharm.com/fmf106/ HELP US SPREAD THE WORD! If you dig the show, please subscribe in iTunes and write us a review! This is what helps us stand out from the crowd and help people find the credible advice they need. Review the show in iTunes! We rely on it! http://www.theartofcharm.com/mobilereview Stay Charming!
© 2020-2025 Ivy Podcast Discovery LLC
